row_id,sent_id,text,aspects,polarity,opinion_sample
0,0_0,"BLA submitted to the FDA, noted January 2, 2024.",regulatory,POS,BLA submitted
1,1_0,"BLA submitted to the FDA, noted January 2, 2024.",regulatory,POS,BLA submitted
2,2_0,"Phase 1 was well-tolerated, and treatment-related adverse events (AEs) were all expected and generally dose-dependent, noted on January 2, 2024.","safety,phase",POS,well-tolerated
3,3_0,"Phase 2/3 results missed a primary endpoint on the LS Mean difference (SE) points between treated and placebo, noted January 2, 2024.","endpoint,effect,phase",NEG,missed
4,4_0,"Phase 1b/2 enrollment completed, noted January 2, 2024.","phase,enrollment",POS,enrollment completed
5,5_0,"Phase 3 dosing initiated, noted January 2, 2024.","phase,clinical",POS,dosing initiated
6,6_0,"Phase 3 enrollment was completed, noted January 2, 2024.","phase,enrollment",POS,enrollment was completed
7,7_0,"Phase 1b third cohort completed, noted January 2, 2024.","phase,clinical",POS,third cohort completed
8,8_0,"Phase 3 data reported that the trial met its primary endpoint and key secondary endpoints, noted January 3, 2024.","endpoint,phase,financial",POS,met
9,9_0,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.","endpoint,phase",POS,met
10,10_0,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.","endpoint,phase",POS,met
13,13_0,"Phase 2/3 trial enrollment completed, noted January 3, 2024.","phase,enrollment",POS,enrollment completed
14,14_0,"Phase 3 enrollment completed, noted January 3, 2024.","phase,enrollment",POS,enrollment completed
15,15_0,"Phase 2 early enrollment completed, noted January 3, 2023.","phase,enrollment",POS,enrollment completed
16,16_0,"Additional Phase 1/2 data reported that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a",phase,POS,achieved
19,19_0,Phase 1 MAD results from 24 healthy volunteers showed that study was well tolerated in participants over the entire dose range and resulted in no safety signals of concern.,"safety,phase",POS,well tolerated
24,24_0,"Phase 2 trial met its primary endpoint, noted January 4, 2024.","endpoint,phase",POS,met
28,28_0,"Phase 1 dosing initiated, noted January 4, 2024.","phase,clinical",POS,dosing initiated
29,29_0,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar","phase,clinical",NEU,statistically significant
30,30_0,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar","phase,clinical",NEU,statistically significant
31,31_0,"Phase 4 data reported that the trial did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler on the primary endpoint, noted January 5, 2024.",endpoint,POS,statistically significant
35,35_0,"NDA submitted to the FDA, noted January 5, 2024.",regulatory,POS,NDA submitted
36,36_0,"NDA submitted to the FDA, noted January 5, 2024.",regulatory,POS,NDA submitted
37,37_0,"FDA Approved on January 5, 2023.",regulatory,POS,FDA Approved
38,38_0,"FDA Approved on January 5, 2023.",regulatory,POS,FDA Approved
46,46_0,"Phase 2b trial met its primary endpoint, noted January 8, 2024.","endpoint,phase",POS,met
51,51_0,Phase 2 data presented at the Biotech Showcase showed that dose was statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after d,phase,POS,statistically significant
53,53_0,"Phase 2a trial did not meet its primary endpoint, noted January 8, 2024.","endpoint,phase",NEG,did not meet
56,56_0,"Phase 2 primary endpoint was met in its randomized, placebo-controlled study, noted on January 8, 2024.","endpoint,phase",POS,met
57,57_0,"Phase 3 trial met its primary endpoint, noted January 8, 2024.","endpoint,phase",POS,met
61,61_0,"Phase 1b data demonstrated potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination developmen","safety,phase",POS,well tolerated
68,68_0,"IND cleared by the FDA, noted January 9, 2024",regulatory,POS,cleared by the FDA
69,69_0,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.","endpoint,safety,phase",POS,met
70,70_0,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.","endpoint,safety,phase",POS,met
71,71_0,"Phase 1 data reported that treatment was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported, noted January 10, 2025.","safety,phase",POS,well tolerated
72,72_0,"Phase 2 32-week interim data reported that 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, wi",phase,POS,achieved
74,74_0,"Phase 2b topline data on ATI-1777 2% QD showed a trend toward significance, ATI-1777 2% BID achieved a statistically significant result in the primary efficacy endpoint at week 4, noted January 10, 2","phase,clinical",POS,achieved
76,76_0,"Phase 2 dosing initiated, noted January 10, 2024.","phase,clinical",POS,dosing initiated
77,77_0,"Phase 1 first cohort completed, noted January 10, 2024.","phase,clinical",POS,first cohort completed
79,79_0,"FDA Approved on January 12, 2024.",regulatory,POS,FDA Approved
80,80_0,"Additional Phase 3 data reported that at Week 4, a statistically significant greater percentage of patients achieved a 50% reduction in EASI scores (EASI-50), with 69.2% of patients treated with roflu",phase,POS,statistically significant
81,81_0,"Approved January 16, 2024.",catalyst,POS,Approved
83,83_0,"Approved January 16, 2024.",catalyst,POS,Approved
84,84_0,"Approved January 16, 2024.",catalyst,POS,Approved
85,85_0,"FDA Approved on January 16, 2024.",regulatory,POS,FDA Approved
86,86_0,"FDA Approved on January 16, 2024.",regulatory,POS,FDA Approved
93,93_1,"Phase 1 trial enrollment completed, noted January 17, 2024","phase,enrollment",POS,enrollment completed
94,94_1,"Phase 1 trial enrollment completed, noted January 17, 2024","phase,enrollment",POS,enrollment completed
99,99_0,"Enrollment completed, noted January 17, 2024.",enrollment,POS,Enrollment completed
102,102_0,"Phase 2/3 IRB approved protocol to asses drug in patients, noted January 17, 2024.",phase,POS,approved
105,105_0,"Phase 2 data reported that the trial met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups, noted January 18","endpoint,phase",POS,met
106,106_0,"Phase 2 data presented at ASCO GI demonstrated early activity with 38% objective response rate including three complete responses, noted January 18, 2024.","phase,clinical",POS,data presented at ASCO
109,109_0,"Phase 3 data presented at ASCO GI reported that treatment reduced the risk of disease progression or death by 23% compared to TACE alone, noted January 19, 2024.","phase,clinical",POS,data presented at ASCO
110,110_1,Alvotech believes it is in position to receive approval on BsUFA,regulatory,POS,approval
111,111_1,Alvotech believes it is in position to receive approval on BsUFA,regulatory,POS,approval
112,112_1,Alvotech believes it is in position to receive approval on BsUFA,regulatory,POS,approval
113,113_1,Alvotech believes it is in position to receive approval on BsUFA,regulatory,POS,approval
116,116_0,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023.",phase,POS,approved
117,117_0,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023.",phase,POS,approved
120,120_0,Phase 2 trial data presented at ASCO-GI showed a major tumor regression in 67.5% of patients.,"phase,clinical",POS,data presented at ASCO
120,120_1,"The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term d",catalyst,POS,achieved
121,121_0,"Phase 3 topline data met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks, noted January 2","endpoint,phase,clinical",POS,met
122,122_0,"Phase 2b enrollment completed exceeding target enrollment (100/90), noted January 22, 2024.","phase,enrollment",POS,enrollment completed
124,124_0,"Phase 3 trial did not meet its primary endpoint, noted January 22, 2024.","endpoint,phase",NEG,did not meet
129,129_0,"FDA Approved on January 23, 2024.",regulatory,POS,FDA Approved
132,132_0,"Phase 1 data presented at the HEAL Initiative Scientific Meeting reported that the trial successfully met its overdose protection endpoints, noted January 25, 2024.",phase,POS,met
135,135_0,"Phase 2 sub-study data reported statistically significant improvements in measures of cardiac structure and function including left ventricular mass index (-11.4 g/m2 Â±19.4, p=0.03), maximum left vent","pvalue,phase",POS,statistically significant
136,136_0,Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients.,"phase,clinical",POS,data presented at ASCO
139,139_0,"Approved January 25, 2024.",catalyst,POS,Approved
140,140_0,"Approved January 25, 2024.",catalyst,POS,Approved
144,144_0,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.","endpoint,phase,clinical",POS,results presented at ASCO
145,145_0,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.","endpoint,phase,clinical",POS,results presented at ASCO
148,148_0,"IND was cleared by the FDA on January 29, 2024.",regulatory,POS,cleared by the FDA
151,151_0,"Preclinical data demonstrated PALI-2108 to be safe and well tolerated, noted January 29, 2024.",safety,POS,well tolerated
152,152_0,"FDA Approved on January 29, 2024.",regulatory,POS,FDA Approved
154,154_0,Phase 1 study published at Journal of Parkinson's Disease showed that data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volu,"safety,phase",NEU,well tolerated
155,155_0,"Pk trial met its primary endpoints, noted January 29, 2024.",endpoint,POS,met
159,159_0,"Phase 3 data met the primary endpoint of non-inferiority to augmentin; and demonstrated statistical superiority, noted January 30, 2024.","endpoint,phase",POS,met
160,160_0,"Phase 3 trial data reported a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) compared to placebo, n","endpoint,phase,clinical",POS,statistically significant
161,161_0,"Phase 3 trial did not meet its primary endpoint, noted January 31, 2024.","endpoint,phase",NEG,did not meet
162,162_0,"Special Protocol Assessment (SPA) dosing initiated, noted January 31, 2024.",clinical,POS,dosing initiated
170,170_0,"Phase 1 trial initial data presented at the Angiogenesis, Exudation, and Degeneration reported that monthly dosing of KSI-501 was safe and well-tolerated, noted February 3, 2024.","safety,phase",POS,well-tolerated
173,173_0,"Phase 2a data reported that 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period, noted February 5, 2024.","endpoint,safety,phase,financial",POS,met
174,174_0,Phase 1 data showed that it well-tolerated and delivered ustekinumab with high bioavailability.,"safety,phase",POS,well-tolerated
177,177_0,"Company submitted the clinical hold complete response to the FDA for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, noted February 5, 2024.","phase,regulatory",NEG,clinical hold
178,178_0,"Phase 3 study met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older, noted February 5, 2024.","endpoint,phase,financial",POS,met
180,180_0,Phase 1/2 clinical data reported a statistically significant improvements in disease severity were reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adju,phase,POS,statistically significant
181,181_0,"Phase 2 trial met its primary endpoint, noted February 6, 2024.","endpoint,phase",POS,met
183,183_0,"Phase 3 trial was not successful, noted February 6, 2024.",phase,POS,successful
186,186_0,"Phase 1/2 data showed that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile, noted February 6, 2024","safety,phase,financial",POS,favorable safety
188,188_0,"Phase 3 data presented at ASCO plenary series noted that the median PFS for patients who received fruquintinib plus paclitaxel was 5.6 months, compared to 2.7 months for those who received paclitaxel","endpoint,phase,clinical",POS,data presented at ASCO
192,192_0,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",regulatory,POS,Breakthrough Therapy
193,193_0,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",regulatory,POS,Breakthrough Therapy
195,195_0,"Phase 3 topline data reported that trial met primary endpoint, noted February 7, 2024.","endpoint,phase,clinical",POS,met
198,198_0,"Phase 2 dosing initiated, noted February 8, 2024.","phase,clinical",POS,dosing initiated
199,199_0,"Phase 2 dosing initiated, noted February 8, 2024.","phase,clinical",POS,dosing initiated
201,201_1,Safety results showed Ampligen is generally well tolerated in the treatment o,safety,POS,well tolerated
203,203_0,"Phase 2 enrollment completed, noted February 8, 2024.","phase,enrollment",POS,enrollment completed
205,205_0,"Phase 2b trial met its primary and secondary endpoints, noted February 9, 2024.","endpoint,phase,financial",POS,met
207,207_0,"IND cleared by the FDA, noted February 9, 2024.",regulatory,POS,cleared by the FDA
208,208_0,"hase 2b/3 enrollment completed, noted February 9, 2024.",enrollment,POS,enrollment completed
211,211_0,"Phase 2 study showed that treatment was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events, noted February 12, 2","safety,phase",NEU,well tolerated
212,212_0,"Fast Track designation granted by the FDA on February 12, 2024.",regulatory,POS,Fast Track
215,215_0,"FDA approved on February 12, 2024.",regulatory,POS,FDA approved
217,217_0,"Type-D meeting with the FDA agreed in a that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec, noted February 12, 2",regulatory,POS,approval
218,218_0,"FDA Cleared IND on February 12, 2024.",regulatory,POS,FDA Cleared
219,219_0,"Phase 1 2nd cohort dosing initiated, noted February 12, 2024.","phase,clinical",POS,dosing initiated
222,222_0,"The FDA cleared IND and granted fast-track designation on February 13, 2024.",regulatory,POS,fast-track
223,223_0,"Phase 3 clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile, noted February 13, 2024.","endpoint,safety,phase,financial",POS,met
224,224_0,"Fast track designation granted by the FDA on February 13, 2024.",regulatory,POS,Fast track
225,225_0,"INDa cleared by the FDA on February 13, 2024.",regulatory,POS,cleared by the FDA
227,227_0,"IND cleared by the FDA, noted February 13, 2024.",regulatory,POS,cleared by the FDA
231,231_0,"Approved February 13, 2024.",catalyst,POS,Approved
232,232_0,"Phase 3 patient enrollment completed, noted February 14, 2024.","phase,enrollment",POS,enrollment completed
234,234_1,"No serious adverse events related to GLSI-100 have been reported to date, noted February 14 2024.",safety,NEG,serious adverse events
240,240_0,"The preclinical study demonstrated successful drug delivery, noted February 14, 2024.",catalyst,POS,successful
244,244_0,"Phase 1 dosing initiated, noted February 15, 2024.","phase,clinical",POS,dosing initiated
245,245_0,"Phase 3 study met the interim primary endpoint, noted February 15, 2024.","endpoint,phase",POS,met
254,254_0,"Phase 1 dosing initiated in China, noted February 16, 2024.","phase,clinical",POS,dosing initiated
255,255_0,"FDA Approved on February 16, 2024.",regulatory,POS,FDA Approved
256,256_0,"Approved February 17, 2024.",catalyst,POS,Approved
257,257_0,"Phase 3 data reported that the trial showed statistically significant and highly clinically meaningful improvement in progression-free survival (PFS), noted February 19, 2024.","endpoint,phase",POS,statistically significant
258,258_1,"Phase 2a trial placed on clinical hold February 20, 2024.","phase,regulatory",NEG,clinical hold
260,260_0,"Fast Track Designation granted by the FDA on February 20, 2024.",regulatory,POS,Fast Track
261,261_1,"FDA granted Fast Track designation, noted February 20, 2024.",regulatory,POS,Fast Track
266,266_0,"Supplemental approval granted by the FDA, noted February 20, 2024.",regulatory,POS,approval
268,268_0,"Phase 1 trial met its primary endpoint, noted February 21, 2024.","endpoint,phase",POS,met
269,269_0,"Phase 2 enrollment completed, noted February 21, 2024.","phase,enrollment",POS,enrollment completed
272,272_0,"Phase 2a data demonstrated a statistically significant benefit in killing ticks compared to placebo, noted February 22, 2024.",phase,POS,statistically significant
276,276_0,"Phase 2 open-label extension data reported that both both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints, noted February 22, 2024.","endpoint,phase,financial",POS,achieved
277,277_0,"PDUFA Priority Review date June 27, 2024.",regulatory,POS,Priority Review
280,280_0,"Phase 1/2a approval to commence dosing, noted February 23, 2024.","phase,regulatory",POS,approval
282,282_0,"Approved February 23, 2024.",catalyst,POS,Approved
283,283_0,"Approved February 23, 2024.",catalyst,POS,Approved
286,286_0,"EAGLE-1 trial met its primary endpoint, noted February 26, 2024.",endpoint,POS,met
287,287_0,"Phase 1 data reported that no severe or serious adverse events were observed in patients treated in Cohort 1, noted February 26, 2024.","safety,phase",NEG,serious adverse events
288,288_0,"Preclinical data reported that treatment achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, noted February 26, 2024.",catalyst,POS,achieved
289,289_0,"Approval noted February 26, 2024.",regulatory,POS,Approval
290,290_0,"Phase 1 presented at Tandem Meetings showed that all eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment, noted February",phase,POS,achieved
292,292_0,"Phase 1 updated clinical data at KOL illustrated a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC, noted Februar","safety,phase",POS,favorable safety
294,294_0,"Approved for expanded indication to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, noted February 26, 2024.",catalyst,POS,Approved
295,295_0,"CRL issued by the FDA, noted February 27, 2024.",regulatory,NEG,CRL
296,296_0,"Phase 2 study met primary and all secondary endpoints, demonstrating reductions in body weight, noted February 27, 2024.","endpoint,phase,financial",POS,met
297,297_0,Phase 2a topline data reported statistically significant improvements (p<0.05) in inflammatory lesions and Investigator's Global Assessment (IGA) score compared to vehicle at Week 12 TP-04 was genera,"pvalue,phase,clinical",POS,statistically significant
299,299_0,"Phase 3 dosing initiated, noted February 27, 2024.","phase,clinical",POS,dosing initiated
300,300_0,"Phase 2 was well tolerated with anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR), noted February 27, 2024.","endpoint,safety,phase",POS,well tolerated
301,301_0,"Phase 1 dosing initiated, noted February 27, 2024.","phase,clinical",POS,dosing initiated
302,302_0,"Phase 3 final results reported met the first co-primary endpoint in the Intent-to-Treat Analysis, however did not meet the co-primary endpoint showing superiority over vehicle, noted February 28, 2024.","endpoint,phase",NEU,met
303,303_0,"Phase 2 topline data reported that the trial met its primary endpoint, noted February 28, 2024.","endpoint,phase,clinical",POS,met
304,304_0,"Preclinical data reported that CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings, noted February 28, 2024.",catalyst,POS,approved
306,306_0,"Phase 2 topline FL results reported that the trial met its primary endpoint, noted February 28, 2024.","endpoint,phase",POS,met
314,314_0,"Phase 3 top-line data reported that the trial met its primary endpoint, however two key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, both of which were not achieved, noted February 29, 2024.","endpoint,phase,financial,clinical",POS,met
315,315_0,"Phase 2 full clinical results presented at ACTRIMS Forum reported that treatment demonstrated significant improvement of vision as measured by low contrast letter acuity (LCLA) through 35 months from randomization, noted February 29, 2024.","phase,clinical",POS,significant improvement
321,321_0,"IND cleared by the FDA, noted February 29, 2024",regulatory,POS,cleared by the FDA
323,323_0,"Additional Phase 2a data reported significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson's Disease, whereas placebo patients experienced a worsening of +1.0 points, noted March 1, 2024","phase,clinical",POS,significant improvement
324,324_0,Additional Phase 3 data reported that due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures.,phase,NEG,missed
325,325_0,"IND Cleared by the FDA, noted March 1, 2024",regulatory,POS,Cleared by the FDA
326,326_3,This is the first time that a relapsed/refractory (r/r) AML patient achieved a CR with CDK9 inhibition monotherapy.,endpoint,POS,achieved
326,326_5,"All key study objectives were met regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity, noted March 1, 2024.",safety,POS,met
327,327_0,"FDA approved on March 1, 2024.",regulatory,POS,FDA approved
332,332_0,"Phase 1 data reported the complete remission was achieved in 64% of patients, with an ORR of 73%, noted March 4, 2024.","endpoint,phase",POS,achieved
337,337_0,"FDA approved on March 4, 2024.",regulatory,POS,FDA approved
338,338_0,"Phase 2/3 last patient dosed, noted March 4, 2024.","phase,clinical",POS,last patient dosed
339,339_0,"Phase 2 enrollment completed, noted March 4, 2024.","phase,enrollment",POS,enrollment completed
345,345_0,"Phase 3 trial stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee.",phase,POS,stopped early due to efficacy
345,345_1,"The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24% for people treated with semaglutide 1.0 mg compared to placebo, noted March 5, 2024.",endpoint,POS,achieved
348,348_0,"Phase 2 trial met the primary endpoint, noted March 5, 2024.","endpoint,phase",POS,met
356,356_0,"IND cleared by the FDA noted, March 5, 2024.",regulatory,POS,cleared by the FDA
357,357_0,"Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated, noted March 5, 2024.","safety,phase",POS,well tolerated
360,360_0,"FDA biosimilar of Xgeva (denosumab) and Prolia (denosumab) approved on March 5, 2024.",catalyst,POS,approved
362,362_0,"CRL issued by FDA on March 6, 2024.",regulatory,NEG,CRL
366,366_0,"Phase 1 dosing initiated, noted March 6, 2024.","phase,clinical",POS,dosing initiated
367,367_0,"Phase 1 dosing initiated, noted March 6, 2024.","phase,clinical",POS,dosing initiated
370,370_0,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024","endpoint,phase",POS,achieved
371,371_0,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024","endpoint,phase",POS,achieved
376,376_0,"Phase 3 data reported that 97% percent (71/73) of participants treated with Biktarvy achieved viral suppression (HIV-1 RNA < 50 copies /ml) as did 97% (36/37) of participants treated with the DTG-based regimen, noted March 6, 2024.",phase,POS,achieved
378,378_0,"Approved March 7, 2024.",catalyst,POS,Approved
379,379_0,"Phase 2b data 12-week data reported that the trial met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate, noted March 7, 2024.","endpoint,phase,financial",POS,met
380,380_0,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.","safety,phase",POS,achieved
381,381_0,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.","safety,phase",POS,achieved
382,382_0,"Phase 3 trial met its primary endpoint, noted March 7, 2024","endpoint,phase",POS,met
387,387_0,"Phase 3 topline results did not meet the primary endpoint, noted March 8, 2024.","endpoint,phase,clinical",NEG,did not meet
389,389_0,"Approved March 8, 2024.",catalyst,POS,Approved
394,394_0,"Phase 2b 24-week data reported that 52% of patients achieved ACR50+PASI100 and up to 61% of patients achieved Minimal Disease Activity (MDA), noted March 10, 2024.",phase,POS,achieved
397,397_0,"Phase 3 results data presented at AAD reported that 56.3% of patients who received Otezla through week 52 achieved static Physician Global Assessment (sPGA) response, noted March 11, 2024.",phase,POS,achieved
398,398_0,"Phase 2 additional data reported that more than three quarters (79.2%) of on-treatment patients achieved at least a 50% reduction in AN count (AN50), 54.2% achieved a 75% reduction (AN75), 20.8% achieved 90% reduction (AN90), and 20.8% achieved complete clearance (100% reduction, AN100), surpassing the 56.3%, 25.0%, 12.5% and 12.5% reductions, respectively, in the vehicle control group, noted March 11, 2024.",phase,POS,achieved
399,399_0,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.","endpoint,phase",POS,met
400,400_0,"Phase 1a/1b clinical hold lifted by the FDA, noted March 11, 2024.",regulatory,NEG,clinical hold
402,402_0,"IND cleared by the FDA, noted March 11, 2024.",regulatory,POS,cleared by the FDA
403,403_0,"Phase 3 data reported that 68% of people experienced significant improvement of at least 75% in disease extent and severity (EASI-75), noted March 11, 2024.","phase,clinical",POS,significant improvement
404,404_0,Phase 1 clinical update presented at virtual investor event showed that treatment was well-tolerated with no dose-limiting toxicities identified.,"safety,phase",POS,well-tolerated
414,414_0,"CRL announced March 11, 2024.",regulatory,NEG,CRL
415,415_0,"Phase 3 study did not meet its primary endpoint, noted March 11, 2024.","endpoint,phase",NEG,did not meet
417,417_0,"Phase 2 OLE dosing initiated, noted March 11, 2024.","phase,clinical",POS,dosing initiated
420,420_0,"Phase 3 data reported a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo, noted March 12, 2024.","endpoint,phase",POS,statistically significant
422,422_0,"Additional Phase 2 durability data reported with significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses, noted March 13, 2024.","phase,clinical",POS,significant improvement
423,423_0,"Phase 2 study met its primary endpoint, noted March 13, 2024.","endpoint,phase",POS,met
425,425_0,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.",safety,POS,well tolerated
426,426_0,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.",safety,POS,well tolerated
427,427_0,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.","safety,phase,clinical",POS,well tolerated
428,428_0,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.","safety,phase,clinical",POS,well tolerated
430,430_0,"Phase 2b top-line data reported that trial did not meet its primary endpoint, noted March 13, 2024.","endpoint,phase,clinical",NEG,did not meet
431,431_0,"Phase 2 top-line data reported that 73% of all patients (22 of 30 patients) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks with no treatment-related SAEs reported, noted March 13, 2024.","safety,sample,phase,clinical",POS,met
432,432_0,"Approval announced March 13, 2024.",regulatory,POS,Approval
435,435_0,"Phase 2 achieved statistically significant liver histologic improvement as measured by at least a 2-point reduction in NAFLD Activity Score (NAS), noted March 13, 2024.",phase,POS,achieved
437,437_0,"Phase 1/2 dosing initiated March 13, 2024.","phase,clinical",POS,dosing initiated
441,441_0,"Approved on March 14, 2024.",catalyst,POS,Approved
442,442_0,"Approved March 14, 2024.",catalyst,POS,Approved
443,443_0,"Approved March 14, 2024.",catalyst,POS,Approved
444,444_0,"Approved March 14, 2024.",catalyst,POS,Approved
445,445_0,"Phase 3 trial met all primary and secondary pharmacokinetic endpoints, noted March 15, 2024.","phase,financial",POS,met
446,446_0,"Additional Phase 1/2 data reported that all six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated, noted March 15, 2024.","safety,phase",POS,achieved
454,454_0,"Phase 2a achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo, noted March 18, 2",phase,POS,achieved
458,458_0,"Approved March 19, 2024.",catalyst,POS,Approved
459,459_0,"Phase 3 topline data reported that the trial met its primary endpoint, noted March 19, 2024.","endpoint,phase,clinical",POS,met
462,462_0,"Phase 3 trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury, noted March 19, 2024.",phase,POS,met
468,468_0,"FDA approved on March 19, 2024.",regulatory,POS,FDA approved
469,469_0,Phase 1/2 clinical data from cohort one (low dose) showed that dosing was well-tolerated with no treatment-emergent SAEs as of 35-week assessment.,"safety,phase",POS,well-tolerated
471,471_0,"Phase 3 trial met primary endpoint, noted March 20, 2024.","endpoint,phase",POS,met
472,472_0,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",catalyst,POS,met
473,473_0,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",catalyst,POS,met
474,474_0,"Phase 2 data reported that eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC, with favorable safety results with no mortality or discontinuations due to advers","safety,phase",POS,favorable safety
475,475_0,"Phase 3 data reported that the trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted March 21, 2024.","endpoint,phase",NEG,did not meet
477,477_0,"IND cleared by the FDA, noted March 21, 2024.",regulatory,POS,cleared by the FDA
480,480_0,"Approved March 22, 2024.",catalyst,POS,Approved
481,481_0,"Phase 2 additional efficacy data showed a statistically significant and durable reduction in ocular pain statistically significant improvement in Tear Film Break-Up Time (TFBUT) throughout the study,","phase,clinical",POS,statistically significant
484,484_0,"Full approval announced March 22, 2024.",regulatory,POS,approval
485,485_0,"EUA approval announced March 22, 2024.",regulatory,POS,approval
487,487_0,"Approved March 22, 2024.",catalyst,POS,Approved
491,491_0,"Phase 3 trial met its primary endpoint, noted March 25, 2024.","endpoint,phase",POS,met
492,492_0,"Approved March 25, 2024.",catalyst,POS,Approved
493,493_0,"FDA Approved on March 25, 2024.",regulatory,POS,FDA Approved
494,494_0,"Phase 1b/2 proof of concept data reported favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, noted March 25, 2024.","effect,safety,phase",POS,favorable safety
497,497_0,CRL issued by FDA on March 25 2024.,regulatory,NEG,CRL
498,498_0,CRL issued by FDA on March 25 2024.,regulatory,NEG,CRL
500,500_0,"Phase 1 trial dosing initiated, noted March 25, 2024.","phase,clinical",POS,dosing initiated
501,501_0,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.","phase,clinical",POS,dosing initiated
502,502_0,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.","phase,clinical",POS,dosing initiated
503,503_0,"Phase 3 enrollment completed, noted March 25, 2024","phase,enrollment",POS,enrollment completed
507,507_0,"ANDA Approval from the FDA, noted March 25, 2024.",regulatory,POS,Approval
508,508_0,"CRL issued March 25, 2024.",regulatory,NEG,CRL
509,509_0,"CRL issued March 25, 2024.",regulatory,NEG,CRL
510,510_0,"Phase 2 data reported a 100% complete response rate in the 45 mg cohort, and in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, noted March 26, 2024",phase,POS,achieved
512,512_0,Phase 1 data was shown to be safe and well-tolerated in the 28-day study with low rates of GI-related adverse events.,"safety,phase",POS,well-tolerated
513,513_0,"FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately, noted March 26, 2024.",regulatory,POS,approval
518,518_0,"Approved March 26, 2024.",catalyst,POS,Approved
522,522_0,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie","endpoint,phase,clinical",POS,met
523,523_0,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie","endpoint,phase,clinical",POS,met
524,524_0,"Phase 2a initial results demonstrated that a single 10mg dose of BPL-003 was well-tolerated and resulted in a rapid onset and durable antidepressant effect in patients living with TRD, noted March 27,","safety,phase",POS,well-tolerated
528,528_0,"Phase 2 data continue to demonstrate antifungal activity and a favorable safety and tolerability profile, noted March 27, 2024.","safety,phase",POS,favorable safety
533,533_0,"Approved March 28, 2024.",catalyst,POS,Approved
535,535_0,"NDA resubmitted to FDA, noted March 28, 2024.",regulatory,POS,NDA resubmitted
536,536_0,"Phase 2 initial data reported that treatment was well-tolerated with an acceptable safety profile, noted March 28, 2024.","safety,phase",POS,well-tolerated
540,540_0,"Phase 2 enrollment completed, noted March 28, 2024.","phase,enrollment",POS,enrollment completed
541,541_0,"Phase 1b preliminary data reported that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, noted March 28, 2024.","safety,phase",POS,well tolerated
547,547_0,"Phase 1b showed that serial procedures were well tolerated without observed dose-limiting toxicity in first cohort, noted March 28, 2024.","safety,phase",POS,well tolerated
548,548_0,"Phase 3 trial met its primary endpoints, noted March 28, 2024.","endpoint,phase",POS,met
550,550_1,"More than 80% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR), noted",catalyst,POS,achieved
551,551_0,"Phase 2 long-term data presented at ASCO reported that the median OS and PFS were 19.6 months (95% CI, 17.9â€“22.4) and 10.2 months, noted April 1, 2024.","endpoint,phase,clinical",POS,data presented at ASCO
552,552_0,"A District Court set aside the injunction and the FDA is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder, noted Ap",regulatory,POS,approval
553,553_0,"FDA Approved on April 1, 2024.",regulatory,POS,FDA Approved
555,555_0,Phase 2/3 trial part 3 dosing initiated with expanded access to include adolescents with AMKD ages 10 to 17 years.,"phase,clinical",POS,dosing initiated
556,556_0,Phase 2 study met its primary endpoint.,"endpoint,phase",POS,met
556,556_1,"Despite improved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but it did not meet statistical signifi","endpoint,financial",NEG,did not meet
558,558_0,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",safety,NEG,serious adverse events
560,560_0,"Phase 3 enrollment completed, noted April 1, 2024.","phase,enrollment",POS,enrollment completed
564,564_0,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",safety,NEG,serious adverse events
566,566_0,"Phase 3 enrollment completed, noted April 1, 2024.","phase,enrollment",POS,enrollment completed
571,571_0,"Phase 2 cohort 4 data reported a a statistically significant reduction of approximately 40% in Rheumatoid Factor in the abiprubart group, noted April 2, 2024.",phase,POS,statistically significant
572,572_0,"Phase 1 US dosing initiated, noted April 2, 2024.","phase,clinical",POS,dosing initiated
574,574_0,"Approved April 2, 2024.",catalyst,POS,Approved
576,576_0,Phase 3 primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours.,"endpoint,phase",POS,met
581,581_0,"Phase 1/2 has been well tolerated in participants at the doses administered, with no dose-limiting toxicities observed.","safety,phase",POS,well tolerated
589,589_0,Phase 2b study did not meet the pre-specified threshold of pâ‰¤0.2.,phase,NEG,did not meet
591,591_0,"IND Cleared by the FDA, noted April 4, 2024.",regulatory,POS,Cleared by the FDA
596,596_0,"Phase 3 trial met the the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted April 5, 2024.","endpoint,phase",POS,met
598,598_0,"Phase 1/2 Data and Safety Monitoring Board (DSMB) convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study, noted April 5, 2024.","safety,phase",POS,approved
600,600_0,"Approved April 5, 2024.",catalyst,POS,Approved
603,603_0,"Preclinical data presented at AACR reported complete tumor regression in the MC38 mouse tumor model, noted April 5, 2024.",clinical,POS,data presented at AACR
604,604_0,"Preclinical data presented at AACR reported that treatment demonstrated inducibility and antitumor activity with regressions in the MC38 mouse tumor model, noted April 5, 2024.",clinical,POS,data presented at AACR
605,605_0,"FDA Approval on April 5, 2024.",regulatory,POS,FDA Approval
606,606_0,"FDA Approval on April 5, 2024.",regulatory,POS,FDA Approval
610,610_0,"Phase 1/2 open-label data presented at AACR reported an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses) with most respo","endpoint,phase,clinical",POS,data presented at AACR
613,613_0,"Phase 1 data presented at AACR reported that in 8 of 16 patients, autogene cevumeran elicited high-magnitude T cells specific to the encoded neoantigens.","sample,phase,clinical",POS,data presented at AACR
614,614_0,"Phase 3 trial met her primary endpoint, noted April 7, 2024.","endpoint,phase",POS,met
615,615_0,"Phase 1/2 trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate, noted April 7, 2024.","endpoint,safety,phase,financial",POS,met
621,621_0,"Phase 1 initial data presented at AACR demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid","safety,phase,clinical",POS,data presented at AACR
622,622_0,Phase 1/2 data presented at AACR showed enhanced clinical efficacy signal in bev naÃ¯ve patients is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-li,"phase,clinical",POS,data presented at AACR
623,623_0,"Preclinical data presented at AACR continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile , Zidesa",clinical,POS,data presented at AACR
624,624_0,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2","phase,clinical",POS,data presented at AACR
625,625_0,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2","phase,clinical",POS,data presented at AACR
628,628_0,Preclinical data presented at AACR showed that data further demonstrate Cogent's capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet,clinical,POS,data presented at AACR
629,629_0,"Preclinical data presented at AACR reported that treatment demonstrated superior immune activation as monotherapy and in combination with PD-(L)1 blockade compared to conventional anti-TIGIT mAb, note",clinical,POS,data presented at AACR
630,630_0,"Phase 1b additional data presented at AACR reported that due to the incidence of TEAE judged related to Mipa and the preliminary activity observed, 15mg was selected as the highest dose to be tested i","phase,clinical",POS,data presented at AACR
631,631_0,"Phase 1 data presented at AACR reported that the combination results in high CR rates in patients with relapsed refractory iNHL, noted April 8, 2024.","endpoint,phase,clinical",POS,data presented at AACR
633,633_0,Phase 1 trial data presented at AACR reported that a majority of patients who received ELI-002 booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.,"phase,clinical",POS,data presented at AACR
635,635_0,Phase 3 results presented at the ASCRS Conference 2024 included co-Primary symptom endpoint of pain met statistical significance and 7 of 11 secondary symptom endpoints met statistical significance (p,"phase,financial",POS,met
636,636_0,"CRL announced April 8, 2024.",regulatory,NEG,CRL
638,638_0,"FDA Approved on April 8, 2024.",regulatory,POS,FDA Approved
641,641_0,"Phase 1 data presented at AACR demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone, noted April 8, 2024.","phase,clinical",POS,data presented at AACR
643,643_0,"Phase 3 enrollment completed, noted April 8, 2024.","phase,enrollment",POS,enrollment completed
646,646_0,"Phase 1 data reported that the initial dose level was well tolerated and demonstrated durable objective responses after MT-601 treatment, noted April 8, 2024.","safety,phase",POS,well tolerated
650,650_0,"FDA granted orphan drug designation, noted April 9, 2024.",regulatory,POS,FDA granted
653,653_0,Preclinical data presented at AACR demonstrated that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibiti,clinical,POS,data presented at AACR
654,654_0,Preclinical data presented at AACR suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expressio,clinical,POS,data presented at AACR
656,656_0,Phase 1/2 early data presented at AACR demonstrated the mechanism.,"phase,clinical",POS,data presented at AACR
658,658_0,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.","safety,clinical",POS,data presented at AACR
659,659_0,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.","safety,clinical",POS,data presented at AACR
660,660_0,"Preclinical data presented at AACR supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue, noted April 9, 2024.",clinical,POS,data presented at AACR
662,662_0,"Phase 2 preliminary data presented at AACR demonstrate that FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those","phase,enrollment,clinical",POS,FPI
663,663_0,"Preclinical data shared at AACR shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses, noted April 9, 2024.",safety,POS,well-tolerated
666,666_0,"Phase 3 dosing initiated, noted April 9, 2024.","phase,clinical",POS,dosing initiated
667,667_0,"Phase 1b cohort 2 patient enrollment completed, noted April 9, 2024.","phase,enrollment",POS,enrollment completed
668,668_0,"Phase 1 results demonstrated that for the first five patients (three of whom were PDAC patients), QN-302 is overall well-tolerated (no SAE) and they have reported a ""good"" quality of life during the d","safety,phase",POS,well-tolerated
671,671_0,"Preclinical data presented at AACR reported that treatment effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models, note",clinical,POS,data presented at AACR
672,672_0,"Phase 1 trial data presented at AACR reported that the best ORR of 94% and a CRR of 83%, noted April 9, 2024.","endpoint,phase,clinical",POS,data presented at AACR
673,673_0,"Preclinical data presented at AACR reported that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect, noted April 9, 2024.",clinical,POS,data presented at AACR
676,676_0,"Phase 3 trial met its primary endpoint, noted April 9, 2024.","endpoint,phase",POS,met
677,677_0,"Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s","endpoint,phase,clinical",POS,data presented at AACR
678,678_0,Phase 1a data presented at AACR reported that BGBâ€‘10188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of,clinical,POS,data presented at AACR
679,679_0,"Phase 1 data presented at AACR reported that selective targeting of EP300 with targeted protein degradation is a safe and effective treatment strategy for advanced tumors, noted April 9, 2024.","phase,clinical",POS,data presented at AACR
681,681_0,Phase 1/2a trial shared at AACR reported that two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg,"sample,phase",POS,achieved
682,682_0,"Preclinical data presented at AACR reported that nab-sirolimus enhanced the cytotoxic effects of fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and HR- breast cancer cells, noted April 1",clinical,POS,data presented at AACR
686,686_0,Phase 1 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested in both narcolepsy type 2 and idiopath,phase,POS,statistically significant
687,687_0,"Preclinical data presented at AACR reported that treatment was highly potent across multiple human tumor cell lines and patient-derived ex vivo tumor models, noted April 10, 2024.",clinical,POS,data presented at AACR
691,691_0,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs","safety,phase,clinical",POS,manageable safety
692,692_0,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs","safety,phase,clinical",POS,manageable safety
695,695_0,"Preclinical data presented at AACR reported that in robust tumor control, leading to significant prolongation of survival in AML xenograft models, noted April 10, 2024.",clinical,POS,data presented at AACR
696,696_0,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we","safety,phase",POS,well tolerated
697,697_0,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we","safety,phase",POS,well tolerated
699,699_0,Phase 2 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%.,phase,POS,statistically significant
700,700_0,"Fast track designation granted by the FDA, noted April 11, 2024.",regulatory,POS,Fast track
705,705_0,"FDA approved on April 11, 2024.",regulatory,POS,FDA approved
707,707_0,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,"sample,phase,clinical",NEG,did not meet
708,708_0,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,"sample,phase,clinical",NEG,did not meet
711,711_0,"Phase 2 enrollment completed, noted April 15, 2024.","phase,enrollment",POS,enrollment completed
715,715_0,"Phase 3 data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo, noted April 15, 2024.","effect,phase",POS,statistically significant
716,716_0,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",phase,POS,achieved
717,717_0,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",phase,POS,achieved
718,718_0,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",phase,POS,achieved
719,719_0,"Phase 3 topline results for the 42 mg Cohort achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, noted April 16, 2024.","endpoint,phase,financial,clinical",POS,achieved
720,720_0,"Phase 2 enrollment completed, noted April 16, 2024.","phase,enrollment",POS,enrollment completed
723,723_0,"Phase 1 dosing initiated, noted April 16, 2024.","phase,clinical",POS,dosing initiated
724,724_0,"Phase 1 additional data presented at AAN demonstrated a favorable safety and tolerability profile in participants with early AD with a relatively low incidence of ARIA-E, noted April 16, 2024.","safety,phase",POS,favorable safety
725,725_0,"Preclinical approval has been received from an independent third-party ethics review board, for human pilot study #2, noted April 16, 2024.",regulatory,POS,approval
728,728_0,"FDA approved on April 16, 2024.",regulatory,POS,FDA approved
729,729_0,"FDA approved on April 16, 2024.",regulatory,POS,FDA approved
730,730_0,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.","endpoint,phase",POS,statistically significant
731,731_0,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.","endpoint,phase",POS,statistically significant
736,736_0,"Phase 1a dosing initiated, noted April 17, 2024.",clinical,POS,dosing initiated
743,743_0,"Phase 3 trial met its primary endpoint, noted April 18, 2024.","endpoint,phase",POS,met
747,747_0,"Phase 1 data presented at AACR results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the difficult to treat platinum-","phase,clinical",POS,data presented at AACR
749,749_0,"IND Cleared by the FDA, noted April 18, 2024.",regulatory,POS,Cleared by the FDA
750,750_0,"Phase 3 showed that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52, not","endpoint,phase",POS,achieved
751,751_0,Phase 2b data presented at AAN reported that PrimeC met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% (p=0,"pvalue,safety,phase",POS,met
752,752_0,"Phase 1 data presented at AAOM resulted in no treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study, noted April 18, 2024.","safety,phase",NEG,serious adverse events
753,753_0,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.","endpoint,phase",POS,met
754,754_0,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.","endpoint,phase",POS,met
755,755_0,"FDA Approved by the FDA, noted April 18, 2024.",regulatory,POS,FDA Approved
758,758_0,"IND cleared by the FDA, noted April 22, 2024",regulatory,POS,cleared by the FDA
759,759_0,"Phase 1 dosing initiated, noted April 22, 2024.","phase,clinical",POS,dosing initiated
761,761_0,"Phase 3 additional results exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints, noted April 22,","phase,financial",POS,statistically significant
763,763_0,"CRL issued by the FDA, noted April 22, 2024.",regulatory,NEG,CRL
767,767_0,"Approved April 22, 2024.",catalyst,POS,Approved
771,771_0,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Ã...sb","endpoint,phase,financial",POS,met
772,772_0,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Ã...sb","endpoint,phase,financial",POS,met
776,776_0,"FDA approved on April 23, 2024.",regulatory,POS,FDA approved
777,777_0,"FDA Approved on April 23, 2024.",regulatory,POS,FDA Approved
778,778_0,"IND cleared by the FDA, noted April 24, 2024.",regulatory,POS,cleared by the FDA
779,779_0,"Phase 3 trial met its primary endpoint, with results demonstrating therapeutic equivalence between AVT05 and Simponi.","endpoint,phase",POS,met
780,780_0,"Phase 2b enrollment completed, noted November 9, 2023.","phase,enrollment",POS,enrollment completed
784,784_0,"FDA Approved, noted April 24, 2024.",regulatory,POS,FDA Approved
787,787_0,"Phase 1 data reported that treatment was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events, noted April 24, 2024.","safety,phase",NEU,well tolerated
790,790_0,"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants, noted April 25, 2024.","phase,clinical",POS,statistically significant
791,791_0,"Trial met both primary endpoints, noted April 25, 2024.",endpoint,POS,met
794,794_0,"Phase 2 enrollment completed, noted April 25, 2024.","phase,enrollment",POS,enrollment completed
795,795_0,"Phase 1 data presented at ECCMID showed that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy v","safety,phase",POS,well tolerated
797,797_0,"Approval announced April 26, 2024.",regulatory,POS,Approval
798,798_0,"Approved for updated label on (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads, noted April 2",catalyst,POS,Approved
799,799_0,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,"safety,phase",POS,statistically significant
800,800_0,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,"safety,phase",POS,statistically significant
801,801_0,"Phase 2 data presented at ESCMID reported that the EDP-235 400 mg arm achieved greater mean change in TSS compared with the placebo arm at all time points, noted April 27, 2024.",phase,POS,achieved
802,802_0,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024","endpoint,phase",POS,statistically significant
803,803_0,"FDA Approved on April 29, 2024.",regulatory,POS,FDA Approved
804,804_0,"Approved April 29, 2024.",catalyst,POS,Approved
805,805_0,"IND cleared by the FDA, noted April 29, 2024.",regulatory,POS,cleared by the FDA
806,806_0,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.","endpoint,phase",NEG,did not meet
807,807_0,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.","endpoint,phase",NEG,did not meet
809,809_0,"NDA resubmitted to the FDA, noted April 29, 2024.",regulatory,POS,NDA resubmitted
811,811_0,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.","safety,phase",POS,well tolerated
812,812_0,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.","safety,phase",POS,well tolerated
818,818_0,"Approved April 29, 2024.",catalyst,POS,Approved
819,819_0,"Approved April 29, 2024.",catalyst,POS,Approved
822,822_0,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.","endpoint,phase,financial",POS,met
823,823_0,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.","endpoint,phase,financial",POS,met
824,824_0,"Updated label approved April 30, 2024.",catalyst,POS,approved
825,825_0,"MTD data reported that all doses were well-tolerated, noted April 30, 2024.",safety,POS,well-tolerated
827,827_0,"Phase 2/3 top line data reported that NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduc","pvalue,phase,clinical",POS,statistically significant
828,828_0,"Phase 1 topline data reported no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity, noted April 30, 2024.","safety,phase,clinical",NEG,serious adverse events
829,829_0,"Phase 1b compassionate use data reported that treatment has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients.","safety,phase",POS,well-tolerated
831,831_0,"Approved April 30, 2024.",catalyst,POS,Approved
833,833_0,"Phase 3 trial met its dual primary endpoint of overall survival (OS), noted May 1, 2024.","endpoint,phase",POS,met
834,834_0,"Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-Î± production in a whole blood (WB) assay, noted May 1, 2024.",catalyst,POS,successful
835,835_0,"Phase 2 30 mg cohort showed a 100% overall response rate in patients with ASXL1 mutation, treatment exhibited strong anti-leukemic activity in 62% of patients with a favorable safety profile across al","safety,phase",POS,favorable safety
836,836_0,"Phase 2a enrollment completed, noted May 1, 2024.","phase,enrollment",POS,enrollment completed
837,837_0,"Phase 2/3 trial enrollment completed noted May 1, 2024.","phase,enrollment",POS,enrollment completed
839,839_0,"Phase 1 trial successful and complete, noted May 1, 2024.",phase,POS,successful
841,841_0,"Phase 3 data reported a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care, noted May 2, 2024.","endpoint,phase",POS,statistically significant
842,842_0,"IND Cleared by the FDA, noted May 2, 2024.",regulatory,POS,Cleared by the FDA
845,845_0,"Preclinical data reported statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth, noted May 2, 2024.",catalyst,POS,statistically significant
846,846_0,Phase 2 trial is well tolerated and has led to encouraging initial efficacy data.,"safety,phase",POS,well tolerated
847,847_0,"Phase 2 trial did not meet its primary endpoint, noted May 3, 2024.","endpoint,phase",NEG,did not meet
848,848_0,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,"phase,clinical",POS,statistically significant
849,849_0,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,"phase,clinical",POS,statistically significant
851,851_1,"Also, patients achieved similar probabilities of DFS r",catalyst,POS,achieved
852,852_0,"Phase 2 data at APA reported clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints, noted May 4, 2024.","phase,financial",POS,statistically significant
855,855_0,"Preclinical data reported that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-",catalyst,POS,approved
856,856_0,"Phase 2 trial did not meet the pre-specified primary endpoint, noted May 6, 2024.","endpoint,phase",NEG,did not meet
858,858_0,"Phase 2 data reported that treatment was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations, with both of these patients remain in CR at 10 an","endpoint,safety,phase",POS,well-tolerated
859,859_0,"IND Cleared by the FDA, noted April 6, 2024.",regulatory,POS,Cleared by the FDA
860,860_0,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp,"endpoint,phase,clinical",NEU,statistically significant
861,861_0,"IND cleared by the FDA, noted May 6 2024.",regulatory,POS,cleared by the FDA
862,862_0,"Preclinical data reported that a statistically significant (FDR adjusted p-value < 0.05) decline in secondary tumor growth rate was found at days 21, 25 and 29 in those mice that received Alpha DaRT",financial,POS,statistically significant
863,863_0,"Phase 2 final data reported statistically significant improvements in key secondary endpoints, such as progression-free survival, (PFS median 5 months versus 2.9 months; Hazard ratio= 0.58) and statis","endpoint,phase,financial",POS,statistically significant
868,868_0,"Phase 3 data showcased previously disclosed data that demonstrated that setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients, noted May 6, 20","sample,phase",POS,achieved
869,869_0,"BLA accepted for priority review by the FDA, noted May 6, 2024.",regulatory,POS,BLA accepted
870,870_0,"BLA accepted for priority review by the FDA, noted May 6, 2024.",regulatory,POS,BLA accepted
871,871_0,"Fast track designation granted by the FDA, noted May 7, 2024.",regulatory,POS,Fast track
872,872_0,"Phase 2 data presented at ARVO demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings, noted May 7, 2024.","phase,clinical",POS,data presented at ARVO
873,873_0,"Phase 2 trial did not meet the primary endpoint, noted May 7, 2024.","endpoint,phase",NEG,did not meet
876,876_0,"Additional Phase 2b data analysis reported a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02), noted May 7, 2024.","pvalue,phase",POS,statistically significant
880,880_0,"Phase 1 trial met its primary and secondary objectives, noted May 8, 2024.","phase,financial",POS,met
881,881_0,"Phase 3 trial data reported that the trial met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo, noted May 8, 2024.","endpoint,phase",POS,met
884,884_0,"Phase 1b dosing initiated, noted May 8, 2024.","phase,clinical",POS,dosing initiated
886,886_0,"Phase 1 dosing initiated, noted May 8, 2024.","phase,clinical",POS,dosing initiated
888,888_0,"Phase 1 data demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall, noted May 8, 2024.","safety,phase",POS,favorable safety
889,889_0,"Phase 2 enrollment completed, noted May 8, 2024.","phase,enrollment",POS,enrollment completed
890,890_0,"Phase 3 study did not meet the study's pre-specified statistical criteria for DFS compared to placebo plus adjuvant chemotherapy, with or without radiotherapy, noted May 9, 2024.",phase,NEG,did not meet
892,892_0,"Phase 1 dosing initiated, noted May 9, 2024.","phase,clinical",POS,dosing initiated
898,898_0,"Trial closed due to clinical hold, noted May 9, 2024.",regulatory,NEG,clinical hold
899,899_0,"Trial closed due to clinical hold, noted May 9, 2024.",regulatory,NEG,clinical hold
904,904_0,Preclinical data presented at ARVO showed that intravitreal administration of 4D-175 to non-human primates (NHP) was safe and well tolerated and resulted in robust transgene expression in the retina a,"safety,clinical",POS,well tolerated
905,905_0,"Phase 2 interim 24-week landmark data presented at ARVO demonstrated that a high dose of 4D-150 (3E10 vg/eye) resulted in robust reductions in overall treatment burden of 89%, percent of patients with","phase,clinical",POS,data presented at ARVO
907,907_0,"Phase 2 topline results reported that serious adverse events occurred in 20.7% of TPIP-treated patients and 40.0% of placebo-treated patients, noted May 9, 2024.","safety,phase,clinical",NEG,serious adverse events
908,908_0,Phase 2 data reported that sevasemten was well tolerated across all 21 participants and significantly reduced biomarkers of muscle damage associated with exercise with a mean post-exercise reduction o,"safety,sample,phase",POS,well tolerated
909,909_0,"IND cleared by the FDA, noted May 9, 2024.",regulatory,POS,cleared by the FDA
912,912_0,"Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023.","safety,phase",POS,achieved
917,917_0,"Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS), noted May 10, 2024.","endpoint,phase",NEG,did not meet
919,919_0,Phase 3 pre-planned analysis data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria.,"endpoint,phase",NEU,met
921,921_0,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",regulatory,POS,Breakthrough Therapy
922,922_0,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",regulatory,POS,Breakthrough Therapy
925,925_0,"Phase 2 trial met primary endpoint, noted May 13, 2024.","endpoint,phase",POS,met
928,928_0,"Phase GLOW2 dosing initiated, noted May 14, 2024.",clinical,POS,dosing initiated
930,930_0,"CRL announced May 14, 2024.",regulatory,NEG,CRL
931,931_0,"Preclinical antiviral activity study resulted in full survival of lethally infected animals was achieved, noted May 14, 2024.",catalyst,POS,achieved
935,935_0,"Phase 1/2 trial dosing initiated, noted May 14, 2024.","phase,clinical",POS,dosing initiated
936,936_0,"Phase 2 data reported that 3 of 3 patients who were naÃ¯ve to FLT3i treatment achieved objective response (2 CR, 1 MLFS), noted May 14, 2024.","endpoint,phase",POS,achieved
940,940_0,"Phase 1 data reported that denifanstat was well-tolerated and no safety signals were reported, noted May 15, 2024.","safety,phase",POS,well-tolerated
942,942_0,Phase 1b/2 data to be shared at ESMO Breast Cancer showed that treatment was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of eit,"safety,phase",POS,well tolerated
947,947_0,"BLA submitted on May 15, 2024.",regulatory,POS,BLA submitted
948,948_0,"Phase 3 data reported that trials met their primary endpoints, noted May 16, 2024.","endpoint,phase",POS,met
951,951_0,"Phase 3 data reported that the trial met both dual primary endpoints, noted May 16, 2024.","endpoint,phase",POS,met
952,952_0,"Phase 1b/2 enrollment completed, noted November 2, 2023.","phase,enrollment",POS,enrollment completed
953,953_0,"Phase 1b/2 enrollment completed, noted November 2, 2023.","phase,enrollment",POS,enrollment completed
954,954_0,"Phase 2 dosing initiated, noted May 16, 2024.","phase,clinical",POS,dosing initiated
957,957_0,"Approved May 16, 2024.",catalyst,POS,Approved
958,958_0,"Approved May 16, 2024.",catalyst,POS,Approved
959,959_0,"Phase 1b data reported that treatment was well tolerated at the maximum administered dose and treatment with mPH-762 provided robust inhibition of tumor growth, noted May 16, 2024.","safety,phase",POS,well tolerated
961,961_0,"Phase 1b/2 last patient dosed completed, noted May 16, 2024.","phase,clinical",POS,last patient dosed
963,963_0,"Approved May 17, 2024.",catalyst,POS,Approved
964,964_0,"Phase 3 enrollment completed, noted May 17, 2024.","phase,enrollment",POS,enrollment completed
976,976_0,"Phase 3 data reported that 70% of patients achieved the composite response endpoint and 25% experienced ALP normalization, noted May 20, 2024.",phase,POS,achieved
981,981_0,"Phase 2 clinical hold removed, noted May 20, 2024.","phase,regulatory",NEG,clinical hold
983,983_0,"Phase 1/2 additional results demonstrate that two 5 Î¼g doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no","safety,phase",POS,well-tolerated
986,986_0,"Phase 3 data reported that both trials met its primary endpoints, noted May 21, 2024.","endpoint,phase",POS,met
987,987_0,"Phase 3 topline data study met its primary endpoint with a statistically significant improvement in the time to failure event, noted May 21, 2024.","endpoint,phase,clinical",POS,met
988,988_0,"Phase 3 dosing initiated, noted May 21, 2024.","phase,clinical",POS,dosing initiated
992,992_0,"Phase 2 results presented at DDW showed an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden at 6 months, noted May 21, 2024.",phase,POS,statistically significant
993,993_0,"Breakthrough Therapy designation (BTD) granted by the FDA, noted May 21, 2024.",regulatory,POS,Breakthrough Therapy
994,994_0,"Phase 3 data showed that nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission, noted May 21, 2024.",phase,POS,achieved
995,995_0,"Phase 2 study met its primary endpoint, noted May 21, 2024.","endpoint,phase",POS,met
996,996_0,"Phase 2 study met its primary endpoint, noted May 21, 2024.","endpoint,phase",POS,met
998,998_0,"Phase 2a enrollment completed, noted May 21, 2024","phase,enrollment",POS,enrollment completed
1003,1003_0,"Approved May 22, 2024.",catalyst,POS,Approved
1008,1008_0,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep","safety,phase",NEU,well tolerated
1009,1009_0,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep","safety,phase",NEU,well tolerated
1010,1010_0,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep","safety,phase",NEU,well tolerated
1011,1011_0,"Phase 1a first-in-human trial confirms ""Pulse-Prime"" hypothesis targeting stimulation of innate and adaptive immune systems, this data to be presented at ASCO 24, noted May 22, 2024.",clinical,POS,data to be presented at ASCO
1017,1017_0,"Phase 1 data published at in video format showed that the study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score",phase,POS,met
1028,1028_0,"Phase 1/2 study as of May 14, 2024, patients receiving the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in dose level 1 cohort achieved a confirmed overall response r",phase,POS,achieved
1031,1031_0,"Phase 1/2 updated data to be presented at ASCO on June 3, 2024.","phase,clinical",POS,data to be presented at ASCO
1035,1035_0,"Phase 1/1b data from ASCO abstract reported that treatment was well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers, noted May 23, 2024.","safety,phase",POS,well tolerated
1036,1036_0,"Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors, noted",phase,POS,approved
1040,1040_0,"Phase 1b data to be presented at ASCO 2024, ASCO abstract released across different NLM sites, overall response rates (ORR) ranged from 18-33%, and disease control rates (DCR) ranged from 67-82%.","endpoint,phase,clinical",POS,data to be presented at ASCO
1049,1049_0,"Phase 2 ASCO abstract showed that treatment administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels, noted May","safety,phase",POS,well tolerated
1051,1051_0,"Preclinical data from ASCO abstract reported that IPH6501, at well-tolerated doses, significantly boosted peripheral NK cell proliferation, drove their accumulation at tumor locations, and effectively",safety,POS,well-tolerated
1061,1061_0,"Phase 1 data from ASCO abstract reported that one patient achieved unconfirmed partial response, and stable disease was observed in 11 patients (24%), noted May 23, 2024.","sample,phase",POS,achieved
1063,1063_0,"NDA and accelerated approval application submitted May 24, 2024.",regulatory,POS,approval
1064,1064_0,Phase 2 clinical efficacy update presented at ASCO abstract showed that monotherapy neoadjuvant treatment was generally well tolerated.,"safety,phase",POS,well tolerated
1066,1066_0,Phase 1 preliminary results from dose escalation in an ASCO abstract shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors,"safety,phase",NEG,DLTs
1068,1068_0,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time.","endpoint,phase,clinical",POS,results to be presented at ASCO
1069,1069_0,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time.","endpoint,phase,clinical",POS,results to be presented at ASCO
1078,1078_0,"Phase 1 data to be presented at ASCO on June 1, 2024, with abstract data reporting that 96.6% of pts had â‰¥1 tx-emergent adverse events, and decreased ctCNA was seen in all complete responders (n=2) an","safety,phase,clinical",POS,data to be presented at ASCO
1079,1079_0,"Phase 1 data from ASCO abstract reported that SVR35 was achieved by all 3 evaluable pts receiving â‰¥10 mg monotherapy, and 3/12 achieved a best response of SVR35, noted May 24, 2024.",phase,POS,achieved
1086,1086_0,"Phase 3 data reported that trial met its primary endpoint, noted May 28, 2024.","endpoint,phase",POS,met
1087,1087_0,"Phase 3 topline data reported that the trial met its primary endpoint, noted May 28, 2024.","endpoint,phase,clinical",POS,met
1090,1090_0,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression","phase,clinical",POS,data to be presented at ASCO
1091,1091_0,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression","phase,clinical",POS,data to be presented at ASCO
1093,1093_0,"Phase 3 trial met its primary endpoint, noted May 28, 2024.","endpoint,phase",POS,met
1097,1097_0,"Phase 3 data reported a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks, noted May 28, 2024.","effect,phase",POS,statistically significant
1098,1098_0,"Phase 3 data reported that patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care, noted",phase,POS,achieved
1101,1101_0,"Phase 1 data from abstract continued to showed that study continues to be well tolerated in the dose expansion portion of the DRAGON trial (Part B), noted May 28, 2024.","safety,phase",POS,well tolerated
1102,1102_0,"Phase 2 data presented at American Epilepsy Society showed azetukalner 20mg achieved clinically meaningful reductions in depression scores on MADRS and HAM-D17 scales, with a 3.04 point difference vs",phase,POS,achieved
1103,1103_1,The data showed NRX-101 achieved similar efficacy to lurasidone on dep,catalyst,POS,achieved
1105,1105_0,Phase 1/2a Safety Review Committee has approved opening enrollment for the 800mg once daily dosing cohort after reviewing favorable safety and pharmacokinetic data from the 550mg cohort.,"safety,phase",POS,favorable safety
1108,1108_0,"Preclinical canine study dosing initiated, noted May 28, 2024.",clinical,POS,dosing initiated
1110,1110_0,"Phase 1 update from ASCO reported that treatment was was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors, noted June 1, 2024.","safety,phase",POS,well tolerated
1111,1111_0,"Phase 1 full data presented at ASCO reported that one patient achieved an unconfirmed partial response and stable disease was observed in 14 additional patients, noted June 1, 2024.","phase,clinical",POS,achieved
1113,1113_0,"Phase 2 ASCO presentation reported a statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunologyâ„¢, and vaccine-induced immune response was demonstrated, no",phase,POS,statistically significant
1114,1114_0,"Phase 2 ASCO presentation reported a statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunologyâ„¢, and vaccine-induced immune response was demonstrated, no",phase,POS,statistically significant
1115,1115_0,"Phase 1 data presented at ASCO reported 92% of evaluable patients treated with INB-200 for GBM exceeded a median PFS of 7 months achieved with the standard-of-care regimen, noted June 1, 2024.","endpoint,phase,clinical",POS,achieved
1116,1116_0,"Phase 2 data presented at ASCO 2024 reported that results showed taletrectinib shrank tumors (confirmed objective response rate, cORR, as assessed by an independent review committee, IRC) in 91% of pa","phase,clinical",POS,data presented at ASCO
1117,1117_0,"Phase 3 data presented at ASCO reported that median duration of follow-up of 36.9 months, selinexor-treated patients had a median PFS of 28.4 months compared to 5.2 months for patients receiving place","endpoint,phase,clinical",POS,data presented at ASCO
1118,1118_0,"Phase 1 initial results presented at ASCO reported one confirmed partial response was observed and eight patients experienced stable disease, noted June 1, 2024.","phase,clinical",POS,results presented at ASCO
1120,1120_0,"Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.",phase,POS,achieved
1121,1121_0,"Phase 2 data shared at ASCO reported that 60% of patients in the EDGE-Gastric study achieved progression-free survival at 12 months, noted June 1, 2024.",phase,POS,achieved
1122,1122_0,"Phase 1a presented at ASCO reported that 5 DLTs were observed with combo tx, no responders and disease control rate (DCR) was 35.0%, noted June 1 2024.",safety,NEG,DLTs
1123,1123_0,"Trial data presented at ASCO reported that the objective response rate [ORR] 1/20 [5%] pts; 7 pts with SD, noted June 1, 2024.","endpoint,clinical",POS,data presented at ASCO
1124,1124_0,"Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.","endpoint,phase,clinical",POS,data presented at ASCO
1125,1125_0,"Phase 1 data presented at ASCO reported to be 1 PR and 8 pts with a best response of SD, noted June 1, 2024.","endpoint,phase,clinical",POS,data presented at ASCO
1126,1126_0,"Phase 1/1b initial combination dose escalation data reported that treatment was generally well-tolerated with enhanced immune activation in tumors, noted June 1, 2024.","safety,phase",POS,well-tolerated
1127,1127_0,"Phase 1/1b initial combination dose escalation data reported that treatment was generally well-tolerated with enhanced immune activation in tumors, noted June 1, 2024.","safety,phase",POS,well-tolerated
1129,1129_0,"Phase 1 initial dose expansion data presented at ASCO reported a median PFS of 14.4 months, noted June 2, 2024.","endpoint,phase,clinical",POS,data presented at ASCO
1132,1132_0,Phase 3 data presented at ASCO showed TAGRISSO reduced the risk of disease progression or death by 84% compared to placebo (hazard ratio [HR] 0.16; 95% confidence interval [CI] 0.10-0.24; p<0.001) as,"pvalue,phase,clinical",POS,data presented at ASCO
1133,1133_0,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing","endpoint,phase,clinical",POS,data presented at ASCO
1134,1134_0,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing","endpoint,phase,clinical",POS,data presented at ASCO
1135,1135_0,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing","endpoint,phase,clinical",POS,data presented at ASCO
1136,1136_0,"Phase 1 trial data presented at ASCO reported 1 PR in Merkel cell carcinoma was observed at 25 mg Q3W, 1 complete response was observed in PD-L1+ NSCLC at the RDE 40 mg Q3W, and 3 pts were continuing","endpoint,phase,clinical",POS,data presented at ASCO
1137,1137_0,"Phase 1 safety and efficacy data presented at ASCO reported that anti-PD-1 naive patients reported a 48.0% (12/25) overall response rate (""ORR"") as per RECIST 1.1(3 CR; 9 PR), noted June 2, 2024.","endpoint,safety,phase,clinical",POS,data presented at ASCO
1138,1138_0,"Phase 3 data presented at ASCO reported statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), not","endpoint,phase,clinical",POS,statistically significant
1139,1139_0,"Phase 3 data presented at ASCO reported a reduced the risk of disease progression or death by 38% by blinded independent central review (BICR) versus chemotherapy in patients with HER2-low expression,","phase,clinical",POS,data presented at ASCO
1140,1140_0,"Phase 1b/2 data presented at ASCO reported that treatment significantly reduced the risk of death by 63% and risk of disease progression by 73% compared to regorafenib, noted June 2, 2024.","phase,clinical",POS,data presented at ASCO
1142,1142_0,"Phase 1b data presented at ASCO reported that the ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) was 10.5% (95% CI, 2.9, 24.8); median progression free survival (mPFS)","endpoint,phase,clinical",POS,data presented at ASCO
1143,1143_0,"Phase 2 trial data presented at ASCO reported that ORR was 45.3% in patients with brain metastases and 32.6% in patients without brain metastases June 2, 2024.","endpoint,phase,clinical",POS,data presented at ASCO
1146,1146_0,"Phase 2a 12-week data from obesity cohort achieved a statistically significant placebo-adjusted mean weight loss of 6.2%, with 67% of patients achieving â‰¥6% weight loss.",phase,POS,achieved
1150,1150_0,"Phase 2 data presneted at ASCO In the newly diagnosed AML cohort, 75% of evaluable patients achieved complete remission or related responses.",phase,POS,achieved
1153,1153_0,"Additional Phase 2 data reported that patients on barzolvolimab experienced a > 8 point improvement in AAS7 (considered a clinically meaningful result) across all doses compared to placebo (p<0.05), n","pvalue,phase",POS,p<0.05
1155,1155_0,"Additional data presented at ASCO reported that at the end of one year, 71% (95% CI: 63-78) of patients in the belantamab mafodotin combination group compared to 51% (95% CI: 42-60) in the bortezomib",clinical,POS,data presented at ASCO
1156,1156_0,"Phase 2 data presented at ASCO resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double histo","phase,clinical",POS,data presented at ASCO
1158,1158_0,"Phase 3 overall survival (OS) did not meet statistical significance at this analysis, neoadjuvant Opdivo with chemotherapy continued to show a clinically important OS improvement trend over chemothera","endpoint,phase",NEG,did not meet
1161,1161_0,Phase 2b data presented at SLEEP reported statistically significant and clinically meaningful increased sleep latency on the Maintenance of Wakefulness Test (MWT) versus placebo across all doses (LS m,phase,POS,statistically significant
1162,1162_0,"Phase 1/2 presented art ASCO showed that study met the primary safety and efficacy endpoints, noted June 3, 2024.","safety,phase",POS,met
1163,1163_0,"Phase 3 topline data reported that the trial met its primary endpoint, note June 3, 2024.","endpoint,phase,clinical",POS,met
1165,1165_0,Phase 1b/2a data presented at ASCO reported that treatment was safe and well tolerated.,"safety,phase,clinical",POS,well tolerated
1166,1166_0,"Phase 3 data reported was observed but not statistically significant, noted June 3, 2024.",phase,NEU,statistically significant
1171,1171_0,"Phase 1 additional data shared at ASCO demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting, noted June 3, 2024.","safety,phase",NEU,manageable safety
1172,1172_0,"Phase 3 trial enrollment completed on May 16, 2023 Phase study achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10, noted","phase,enrollment",POS,achieved
1174,1174_0,"Phase 2 trial data presented at ASCO reported that 12-month overall survival (""OS"") rate of 69%, a median overall survival (mOS) of 17.5 months, and a 30% overall response rate (ORR) at the time of da","endpoint,phase,clinical",POS,data presented at ASCO
1175,1175_0,"Phase 1 data presented at SLEEP 2024 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested, noted Ju",phase,POS,statistically significant
1182,1182_0,Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie,"phase,clinical",POS,data presented at ASCO
1183,1183_0,Phase 3 data presented at ASCO showed that at 34.9 months it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patie,"phase,clinical",POS,data presented at ASCO
1184,1184_0,"Phase 2 data presented at ASCO from its 12-month study results demonstrated an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data, noted June","phase,clinical",POS,data presented at ASCO
1187,1187_0,"Phase 3 full data presented at ASCO reported that the treatment improved the risk-to-benefit profile of the combination treatment, maintaining efficacy with significantly fewer acute and long-lasting","phase,clinical",POS,data presented at ASCO
1188,1188_0,"Phase 2 interim analysis presented at ASCO reported that an ORR (25% vs 7%), disease control rate (DCR) (63% vs 40%), and decrease in CA19-9 level (61% decrease vs. 34% increase), noted June 3, 2024.","endpoint,phase,clinical",POS,analysis presented at ASCO
1190,1190_0,"Approved April 6, 2024.",catalyst,POS,Approved
1191,1191_0,Preclinical data presented at ASCO demonstrated the potential of combining Celularity's placental-derived cell therapy platform with currently available antibody therapies to address difficult-to-trea,clinical,POS,data presented at ASCO
1192,1192_0,"Phase 2 data presented at ASCO reported that confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted June","endpoint,phase,clinical",POS,data presented at ASCO
1197,1197_0,"Phase 2 full data presented at SLEEP 2024 showed that study was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and bra","safety,phase",POS,well tolerated
1198,1198_0,"Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-naÃ¯ve and 3/7 in prior MET",phase,POS,MET
1199,1199_0,"Phase 3 results published at ASCO showed that as of the cutoff, in 15 evaluable patients, the confirmed partial response rate was 53% (8/15), including 6/8 responses in TKI-naÃ¯ve and 3/7 in prior MET",phase,POS,MET
1200,1200_0,"IND cleared by the FDA, noted June 3, 2024.",regulatory,POS,cleared by the FDA
1203,1203_0,Phase 2 interim results presented at ASCO showed an verall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of,"phase,clinical",POS,results presented at ASCO
1210,1210_0,"Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.","endpoint,phase,clinical",POS,data presented at ASCO
1211,1211_0,"Phase 1b combination expansion data presented at ASCO reported that the ORR was 40% with 3 of the 4 responses confirmed, noted June 3, 2024.","endpoint,phase,clinical",POS,data presented at ASCO
1216,1216_0,"Phase 2 data presented at ASCO showed an Overall Response Rate (ORR) of 60%, noted June 4, 2022.","endpoint,phase,clinical",POS,data presented at ASCO
1217,1217_0,"Phase 3 topline data of its single infusion 30 mg/kg dose met the primary endpoint with a highly statistically significant 2.4-fold improvement in GBS disability score versus placebo at week 8, noted","endpoint,phase,clinical",POS,met
1218,1218_0,"Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo.",phase,POS,achieved
1218,1218_1,"Additionally, up to 57% achieved â‰¥1-",catalyst,POS,achieved
1219,1219_0,"Phase 2b 52-week biopsy data showed that up to 75% of VK2809-treated patients achieved NASH resolution with no worsening of fibrosis, compared to 29% for placebo.",phase,POS,achieved
1219,1219_1,"Additionally, up to 57% achieved â‰¥1-",catalyst,POS,achieved
1220,1220_0,"Phase 2 data cohort 5 from PROPEL 2 reported a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.",phase,POS,statistically significant
1221,1221_0,Phase 1 data presented at ASCO showed that at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs),"endpoint,phase,clinical",POS,data presented at ASCO
1222,1222_0,Phase 2 top-line data showed that 20% of all patients and 29% of those with moderate to severe disease who completed 24 weeks of treatment achieved a SALT score â‰¤20 (reduction in hair loss).,"phase,clinical",POS,achieved
1223,1223_0,"Phase 1 dose escalation data presented at ASCO 2024 showed an overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96%, noted June 4, 2024.","endpoint,phase,clinical",POS,data presented at ASCO
1226,1226_0,Phase 3 late-breaking data presented at ASCO demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population.,"phase,clinical",POS,data presented at ASCO
1228,1228_0,"Fast Track designation granted by the FDA, noted June 4, 2024.",regulatory,POS,Fast Track
1230,1230_0,"Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.",phase,POS,achieved
1231,1231_0,"Additional Phase 2 data presented at EASL reported that 50% (3 of 6) achieved the combined endpoint, noted June 5, 2024.",phase,POS,achieved
1236,1236_0,"Phase 3 data reported that 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeks, noted June 5, 2024.",phase,POS,achieved
1237,1237_0,"Fast track designation granted by the FDA, noted June 5, 2024.",regulatory,POS,Fast track
1238,1238_0,"Phase 3 interim results presented at EASL reported that 73% achieved the clinically meaningful composite response endpoint, with 42% experiencing ALP normalization, noted June 5, 2024.",phase,POS,achieved
1243,1243_0,"Phase 2 interim data reported that statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, ranging from the original Wuhan strain through Delta and",phase,POS,statistically significant
1246,1246_0,"Phase 3 trial met its primary endpoint, showing a statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week placebo-controlled period.","endpoint,phase",POS,met
1248,1248_0,"Phase 2b data reported that treatment statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, noted June 6, 2024.","phase,financial",POS,statistically significant
1257,1257_0,"Full clinical hold place June 6, 2024.",regulatory,NEG,clinical hold
1258,1258_0,"Full clinical hold announced June 6, 2024.",regulatory,NEG,clinical hold
1259,1259_0,"Approved June 6, 2024.",catalyst,POS,Approved
1260,1260_0,"Phase 1a received IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial, noted June 6, 2024.",safety,POS,favorable safety
1261,1261_0,"BLA submitted June 17, 2024.",regulatory,POS,BLA submitted
1262,1262_0,"Approved vaccine submitted to the FDA for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1., noted June 7, 2024.",catalyst,POS,Approved
1264,1264_0,"Approved June 7, 2024.",catalyst,POS,Approved
1265,1265_0,Phase 2b 48-week data presented at EASL reported statistically significant improvements across key markers of liver health.,phase,POS,statistically significant
1266,1266_0,"Phase 3 data reported that the trial met its primary endpoints, noted June 10, 2024.","endpoint,phase",POS,met
1269,1269_0,"Phase 2a study did not meet the primary endpoint for lowering intraocular pressure, leading the company to discontinue the program and associated ophthalmology pipeline, noted June 10, 2024.","endpoint,phase",NEG,did not meet
1270,1270_0,"Phase 2a received approval from an Israeli review board to initiate open-label study, noted June 10, 2024.","phase,regulatory",POS,approval
1272,1272_0,"Phase 2 dosing initiated, noted June 10, 2024.","phase,clinical",POS,dosing initiated
1273,1273_0,"Phase 2 data reported that the efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on",phase,POS,achieved
1274,1274_0,"Phase 2b data presented at EASL reported that â‰¥1-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) do","pvalue,phase",POS,p<0.05
1275,1275_0,"Phase 2b data presented at EASL reported that â‰¥1-stage improvement in fibrosis with no worsening of MASH after 24 weeks of treatment for both the 50 mg EFX (41%, p<0.05) and 28 mg EFX (39%, p<0.05) do","pvalue,phase",POS,p<0.05
1280,1280_0,"Phase 2a enrollment was completed with initial data showing an overall response rate (ORR) of 33% and 50% achieved to date in 60 mg QW and 30 mg BIW cohorts, noted June 10, 2024.","endpoint,phase,enrollment",POS,achieved
1283,1283_0,"FDA approved on June 10, 2024.",regulatory,POS,FDA approved
1286,1286_0,"Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.","endpoint,phase,clinical",POS,met
1287,1287_0,"Phase 2 topline data reported that the study met its primary endpoint, noted June 11, 2024.","endpoint,phase,clinical",POS,met
1290,1290_0,"FDA Approved on June 11, 2024.",regulatory,POS,FDA Approved
1291,1291_0,"FDA Approved on June 11, 2024.",regulatory,POS,FDA Approved
1298,1298_0,"Phase 1 first cohort completed, noted June 11, 2024.","phase,clinical",POS,first cohort completed
1304,1304_0,"Phase 2 trial initiated and IND cleared by the FDA, noted June 12, 2024.","phase,regulatory",POS,cleared by the FDA
1305,1305_0,"Preclinical data presented at EULAR demonstrated selective enhancement of Treg Cell function through novel agonistic mechanism, noted June 12, 2024.",clinical,POS,data presented at EULAR
1306,1306_0,"Approved June 12, 2024.",catalyst,POS,Approved
1308,1308_0,"Phase 3 trial did met its primary endpoint, noted June 12, 2024.","endpoint,phase",POS,met
1309,1309_0,"Phase 3 trial did not meet its primary endpoint, noted June 12, 2024.","endpoint,phase",NEG,did not meet
1311,1311_0,"Phase 3 met its primary vaccine efficacy endpoint demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax in participants 12 years of age and older, noted June 13, 2024.",phase,POS,met
1314,1314_0,Phase 1/2 data presented at EHA reported that treatment was well tolerated up to doses of 6 mg/kg QW with observed clinical benefit in adult pts with R/R AMLand a maximum response rate seen at a targ,"safety,phase",POS,well tolerated
1315,1315_0,Phase 1/2 data presented at EHA reported that treatment was well tolerated up to doses of 6 mg/kg QW with observed clinical benefit in adult pts with R/R AMLand a maximum response rate seen at a targ,"safety,phase",POS,well tolerated
1316,1316_0,"Phase 3 data presented at EULAR reported significant improvement on the primary pain endpoint and on all six key secondary endpoints, noted June 14, 2024.","endpoint,phase,financial,clinical",POS,significant improvement
1317,1317_0,"Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.",phase,POS,achieved
1318,1318_0,"Phase 2 trial data presented at EHA reported that 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted June 14, 2024.",phase,POS,achieved
1322,1322_0,"Phase 1 initial data in healthy volunteers shared at EHA reported that mean serum iron reduction of more than 50% from baseline was achieved for both 150- and 300-mg doses, noted June 14, 2024.",phase,POS,achieved
1324,1324_0,"Phase 2 presented at EHA continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts, noted June 14, 2024.","safety,phase",POS,well-tolerated
1328,1328_0,Phase 1/2 manufacturing data presented at EHA reported that reproducibly met the high viability threshold across 14 development runs using healthy and sickle cell trait donor cells and nine GMP clinic,phase,POS,met
1330,1330_0,Phase 1/2 data presented at EHA reported that treatment was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem,"safety,phase",POS,well-tolerated
1334,1334_0,"Approved June 14, 2024.",catalyst,POS,Approved
1343,1343_0,"Phase 1 data presented at EULAR reported that treatment was generally well tolerated, with total B cell counts were dose-dependently reduced in all participants, noted June 14, 2024.","safety,phase,clinical",POS,well tolerated
1344,1344_0,"Phase 1/2 additional data presented at EHA showed that out of 20 evaluable subjects across all treatment lines, 45% achieved a composite complete remission (CRc), including 89% with poor prognosis cy",phase,POS,achieved
1346,1346_0,"Approved June 14, 2024.",catalyst,POS,Approved
1348,1348_0,"Phase 1b data reported that 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, noted June 15, 2024.","endpoint,sample,phase",POS,achieved
1354,1354_0,"Phase 2b interim analysis demonstrated a statistically significant (-3.82, p<0.0001) improvement in pruritus for volixibat and a placebo-adjusted difference of -2.32 points in the primary endpoint, p=","endpoint,pvalue,phase",POS,statistically significant
1359,1359_0,"Phase 3 data presented at EHA reported that 42.3% (n=55/130) of patients in the mitapivat arm achieved a hemoglobin response, compared to 1.6% (n=1/64) of patients in the placebo arm, noted June 17, 2","sample,phase",POS,achieved
1361,1361_0,"Approved June 17, 2024.",catalyst,POS,Approved
1362,1362_0,"Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.","endpoint,phase",NEG,did not meet
1363,1363_0,"Phase 3 trial did not meet its primary endpoint, noted June 17, 2024.","endpoint,phase",NEG,did not meet
1364,1364_0,"Approved June 17, 2024.",catalyst,POS,Approved
1365,1365_0,Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical,"endpoint,phase,clinical",POS,met
1366,1366_0,Phase 3 topline data reported that it met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population but failed to achieve statistical,"endpoint,phase,clinical",POS,met
1367,1367_0,"Phase 2 placed on clinical hold due to 2 deaths in the DENALI study, noted June 18, 2024.","phase,regulatory",NEG,clinical hold
1368,1368_0,"Phase 2 study placed in clinical hold after 2 recent deaths presumed sepsis in the study, noted June 18, 2024.","phase,regulatory",NEG,clinical hold
1369,1369_0,"Phase 3 trial dosing initiated, noted June 18, 2024.","phase,clinical",POS,dosing initiated
1370,1370_0,Phase 3 trial did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a subgroup of p,"endpoint,phase",NEG,did not meet
1372,1372_0,"Phase 3 topline results reported that the trial met the primary endpoint of change from baseline at Week 6 on the Montgomery-Ã...sberg Depression Rating Scale (MADRS) total score versus placebo, noted Ju","endpoint,phase,clinical",POS,met
1375,1375_0,"Approved June 18, 2024.",catalyst,POS,Approved
1376,1376_0,"Approved June 18, 2024.",catalyst,POS,Approved
1378,1378_0,"Phase 1b dosing initiated, noted June 18, 2024.","phase,clinical",POS,dosing initiated
1381,1381_0,"Phase 1/2 trial presented at the IRSF ASCEND 2024 Rett Syndrome National Summit showed that high-dose has been well-tolerated, and low-dose continues to show a favorable safety profile, the company al","safety,phase",POS,well-tolerated
1382,1382_0,"Phase 1/2 data in the 65-subject Phase 2 portion, the Natrunix arm showed fewer overall adverse events, a 28% reduction in serious adverse events, 33% less hospitalization days, and improved symptoms","safety,phase",NEG,serious adverse events
1383,1383_0,"FDA Approval on June 18, 2024.",regulatory,POS,FDA Approval
1385,1385_0,"IND approved in China, noted June 19, 2024.",catalyst,POS,approved
1391,1391_0,"Phase 1/2a preliminary data from Phase 1, involving healthy participants, showed ELE-101 was well-tolerated with no serious adverse events, demonstrating a dose-proportional PK profile and inducing sh","safety,phase",NEU,well-tolerated
1392,1392_0,"Preclinical data demonstrated statistically significant, dose-dependent increases in seizure threshold and protection against induced seizures.",catalyst,POS,statistically significant
1392,1392_1,"While not statistically significant, preliminary data pr",endpoint,NEU,statistically significant
1394,1394_0,"IND cleared by the FDA, noted June 20, 2024.",regulatory,POS,cleared by the FDA
1396,1396_0,"NDA submitted to FDA, noted June 20, 2024.",regulatory,POS,NDA submitted
1397,1397_0,"NDA submitted to FDA, noted June 20, 2024.",regulatory,POS,NDA submitted
1398,1398_1,"MM120 met its primary and key secondary endpoints and demonstrated a rapid, clinically meaningful, and","endpoint,financial",POS,met
1399,1399_0,"Phase 2b trial did not meet primary endpoint, noted June 20, 2024.","endpoint,phase",NEG,did not meet
1400,1400_0,"FDA Approved on June 21, 2024.",regulatory,POS,FDA Approved
1401,1401_0,"NDA resubmitted to FDA, noted June 21, 2024.",regulatory,POS,NDA resubmitted
1403,1403_0,Phase 3 trial data presented at ADA showed that tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction,"endpoint,phase,financial,clinical",POS,achieved
1404,1404_0,"FDA approved on June 21, 2024.",regulatory,POS,FDA approved
1405,1405_0,"FDA approved on June 21, 2024.",regulatory,POS,FDA approved
1410,1410_0,"Preclinical data presented at ADA shown to be superior compared to tirzepatide, noted June 22, 2024.",clinical,POS,data presented at ADA
1411,1411_0,"Data presented at ADA proves inhaled insulin is as effective as usual care for adults living with T1D meeting the primary endpoint, noted June 22, 2024.","endpoint,clinical",POS,Data presented at ADA
1414,1414_0,Phase 2 data presented at ADA highlights the impressive lean mass preservation achieved with pemvidutide.,"phase,clinical",POS,achieved
1416,1416_0,Preclinical data presented at ADA showed that a single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model.,clinical,POS,data presented at ADA
1418,1418_0,"Phase 1b data from cohort 3 in the 3 mg/kg dose showed a continued mechanistic dose response, with statistically significant increases in urinary PC1 and PC2 compared to placebo, noted June 24, 2024.",phase,POS,statistically significant
1419,1419_1,"Fast track designation granted by the FDA on June 24, 2024.",regulatory,POS,Fast track
1420,1420_0,"Phase 3 topline data reported that study met the main goal in a late-stage study testing it as a treatment for a type of heart disease, noted June 24, 2024.","phase,clinical",POS,met
1424,1424_0,"The IND cleared by the FDA on June 24, 2024",regulatory,POS,cleared by the FDA
1425,1425_0,"Phase 1 top-line data of gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity, noted June 24, 2024.","phase,clinical",POS,statistically significant
1426,1426_0,"Phase 3 reported the successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis using MAT2203, their oral formulation of amphotericin B.",phase,POS,successful
1427,1427_0,"Phase 2b showed it was well-tolerated across 1,027 patients, with an adverse event profile comparable to placebo, noted June 24, 2024.","safety,sample,phase",NEU,well-tolerated
1428,1428_0,Phase 2 data presented at Bi-Annual In-SIGHT ppeared safe and well-tolerated with a median 17% reduction in the total polyp burden at 12 months compared with baseline and an overall 75% non-progressio,"safety,phase",POS,well-tolerated
1431,1431_0,"FDA Approved on June 24, 2024.",regulatory,POS,FDA Approved
1433,1433_0,"IND cleared by the FDA, noted June 24, 2024.",regulatory,POS,cleared by the FDA
1434,1434_0,"Preclinical data recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs against influenza, noted June 24, 2024.",catalyst,POS,approved
1436,1436_0,"Preclinical data presented at ADA support the potential of SRK-439 to increase lean mass and contribute to a favorable body composition following withdrawal from GLP-1 RA treatment, noted June 24, 202",clinical,NEU,withdrawal
1437,1437_0,"Preclinical data presented at ADA showed that treatment induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes, noted June 24,",clinical,POS,data presented at ADA
1442,1442_0,"Phase 3 trial did not meet statistical significance for the primary endpoint of disease-free survival (DFS) versus placebo, noted June 25, 2024.","endpoint,phase",NEG,did not meet
1443,1443_0,"Phase 3 trial demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint, noted June 25, 2024.","endpoint,phase",POS,statistically significant
1444,1444_0,"Phase 3 dosing initiated, noted June 25, 2024.","phase,clinical",POS,dosing initiated
1448,1448_0,"Phase 1b/2a data reported a 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated","safety,phase",POS,well-tolerated
1449,1449_0,"Phase 3 data showed no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose over seven days of as-needed treatment.",phase,NEG,withdrawal
1452,1452_0,"CRL issued June 25, 2024.",regulatory,NEG,CRL
1454,1454_0,"Pivotal trial topline results reported that the trial met its standard bioequivalence (BE) criteria, noted June 25, 2024.","phase,clinical",POS,met
1455,1455_0,"Phase 1 data treatment was well-tolerated, with rapid viral elimination and no disease progression observed.","safety,phase",POS,well-tolerated
1460,1460_0,"Phase 3 data reported that the trial met its primary endpoint, noted June 26, 2024.","endpoint,phase",POS,met
1463,1463_0,"Phase 3 trial did not meet its primary endpoint, noted June 26, 2024.","endpoint,phase",NEG,did not meet
1464,1464_0,"Phase 1 data presented at ESMO GI reported an overall response (OR) across tumor types was 18.2% (n=33), including four confirmed and two unconfirmed partial responses (PR), noted June 26, 2024.","endpoint,sample,phase,clinical",POS,data presented at ESMO
1465,1465_0,"Approved June 26, 2024.",catalyst,POS,Approved
1466,1466_0,"Approved June 26, 2024.",catalyst,POS,Approved
1467,1467_0,"CRL announced June 27, 2024.",regulatory,NEG,CRL
1468,1468_0,"Approved June 27, 2024.",catalyst,POS,Approved
1469,1469_0,"Approved June 27, 2024.",catalyst,POS,Approved
1470,1470_0,"Phase 2 data reported that 100% (6/6) of evaluable participants who had completed the six-month study achieved target ANC increase, noted June 27, 2024.",phase,POS,achieved
1472,1472_0,"Phase 1/2 demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level, noted June 27, 2024.","safety,phase",POS,favorable safety
1476,1476_0,"Second part of Phase 3 trial enrollment completed, noted June 27, 2024","phase,enrollment",POS,enrollment completed
1477,1477_0,Phase 2b data reported that the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo i,phase,POS,met
1483,1483_0,"CRL issued June 28, 2024.",regulatory,NEG,CRL
1485,1485_0,"Phase 2 data reported that in the NEST-2 cohort, 78% (7/9) of MSS patients achieved pathologic responses of at least 50% tumor regression, with 56% (5/9) reaching complete pathologic responses, noted",phase,POS,achieved
1487,1487_0,"Phase 1 data reported that the trial met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events, noted July 1, 2024.","safety,phase",NEU,met
1489,1489_0,Phase 3 study showed that the objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did no,"phase,enrollment",POS,fully enrolled
1490,1490_0,"Phase 2 enrollment completed for the study in Europe at 0.3 mg/kg dose level, with data expected later this year.","phase,enrollment",POS,enrollment completed
1492,1492_0,"Phase 1b study dosing initiated, noted July 1, 2024.","phase,clinical",POS,dosing initiated
1493,1493_0,"Phase 1b study dosing initiated, noted July 1, 2024.","phase,clinical",POS,dosing initiated
1494,1494_0,"Phase 2b trial met primary endpoint with statistical significance, noted July 2, 2024.","endpoint,phase",POS,met
1496,1496_0,"FDA approval for ANDA, noted July 2, 2024.",regulatory,POS,FDA approval
1497,1497_0,Phase 3 update showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.,phase,POS,statistically significant
1497,1497_1,Buntanetap's activity resulted in statistically significant improvem,catalyst,POS,statistically significant
1498,1498_0,"Fast track designation, granted by the FDA, noted July 2, 2024.",regulatory,POS,Fast track
1500,1500_0,"Phase 1 data presented at ISPNO 2024 showed that overall, the treatment was well tolerated by patients.","safety,phase",POS,well tolerated
1503,1503_0,"Approved July 2, 2024.",catalyst,POS,Approved
1505,1505_0,"Phase 3 additional results from study presented at the 7th World Bronchiectasis Conference confirmed that the study met its primary endpoint, with both 10 mg and 25 mg doses significantly reducing the","endpoint,phase",POS,met
1508,1508_0,"Phase 2 trial data reported significant improvement of the viability of segments from baseline to six months, noted July 8, 2024.","phase,clinical",POS,significant improvement
1509,1509_0,"Fast track designation granted by the FDA, noted July 8, 2024.",regulatory,POS,Fast track
1510,1510_0,"Phase 2b topline data reported that the trial did not meet its primary endpoint of efficacy against moderate or severe acute gastroenteritis (AGE) events due to GI.1 or GII.4 norovirus genotypes, note","endpoint,phase,clinical",NEG,did not meet
1516,1516_0,"Phase 2 trial ethic approval announced July 9, 2024.","phase,regulatory",POS,approval
1517,1517_0,"BLA resubmitted on July 9, 2024.",regulatory,POS,BLA resubmitted
1518,1518_0,"BLA resubmitted on July 9, 2024.",regulatory,POS,BLA resubmitted
1521,1521_1,"No discontinuations or serious adverse events were reported, noted July 9, 2024.",safety,NEG,serious adverse events
1528,1528_0,"FDA Approved on July 9, 2024.",regulatory,POS,FDA Approved
1530,1530_0,"Swine Model data reported that treatment was well-tolerated by all of the pigs and demonstrated a long-term, slow-release profile, noted July 10, 2024.",safety,POS,well-tolerated
1531,1531_0,"Data reported a 68% improvement in responder rate results from patients who achieved both the conjunctival staining ""sign"" and ocular pain ""symptom"" endpoints, noted July 10, 2024.",catalyst,POS,achieved
1536,1536_0,"CRL announced July 10, 2024.",regulatory,NEG,CRL
1538,1538_0,"Phase 2 trial enrollment completed, noted July 11, 2024.","phase,enrollment",POS,enrollment completed
1539,1539_0,"Fast Track designation application submitted to the FDA, noted July 11, 2024.",regulatory,POS,Fast Track
1541,1541_0,"Phase 1/2 dosing initiated in China, noted July 12, 2024.","phase,clinical",POS,dosing initiated
1542,1542_0,"NDA submitted July 12, 2024.",regulatory,POS,NDA submitted
1545,1545_0,"Phase 1a data reported that treatment was well tolerated with no treatment-related serious adverse events, noted July 15, 2024.",safety,NEU,well tolerated
1549,1549_0,"FDA ANDA Approval on July 15, 2024.",regulatory,POS,Approval
1550,1550_0,"Phase 2a final 320mg data of the cohort met its primary endpoint of safety, demonstrating that bexotegrast was well tolerated up to 40 weeks of treatment, noted July 15, 2024.","endpoint,safety,phase",POS,met
1551,1551_0,"IND Cleared by the FDA, noted July 15, 2024.",regulatory,POS,Cleared by the FDA
1552,1552_0,"FDA granted Regenerative Medicine Advanced Therapies (RMAT) designation, noted July 15, 2024.",regulatory,POS,FDA granted
1555,1555_0,Company received FDA approval to use a new crystalline form of their drug buntanetap in future clinical trials for neurodegenerative disorders following June's 2024 patent filings for the new crystal,regulatory,POS,FDA approval
1558,1558_0,"Phase 2a trial enrollment completed, noted July 16, 2024.","phase,enrollment",POS,enrollment completed
1559,1559_0,"IND Cleared by the FDA, noted July 16, 2024.",regulatory,POS,Cleared by the FDA
1560,1560_0,Phase 2 24-week data reported reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection,"sample,phase",POS,achieved
1566,1566_0,"Phase 3 enrollment completed, noted July 18, 2024","phase,enrollment",POS,enrollment completed
1567,1567_0,"Phase 2 study update following a Type C Meeting with the FDA which stated that it was open to considering the accelerated approval pathway, noted July 18, 2024.","phase,regulatory",POS,approval
1568,1568_0,"Phase 2 preliminary data showed a 19.4% overall response rate and 90% 6-month survival rate, and FDA advice against seeking Accelerated Approval.","phase,regulatory",POS,Approval
1569,1569_1,"A top responder patient achieved 9.1 months of progression-free survival, quadrupling the PFS of patients in similar studies.",endpoint,POS,achieved
1570,1570_0,"FDA Approved on July 18, 2024.",regulatory,POS,FDA Approved
1571,1571_0,"Phase 1 SAD data reported no serious adverse events or severe treatment-emergent adverse events, noted July 18, 2024.","safety,phase",NEG,serious adverse events
1572,1572_0,"Phase 3 trial met its primary end point, noted July 18, 2024.",phase,POS,met
1574,1574_0,Phase 3 did not meet the primary endpoint of reduced acute pelvic pain compared to the Sham treatment at three months post-procedure.,"endpoint,phase",NEG,did not meet
1577,1577_0,"IND Cleared by the FDA, noted July 22, 2024",regulatory,POS,Cleared by the FDA
1584,1584_0,"Phase 3 Type-C meeting FDA feedback resulted in successful preparatory regulatory interactions for the design of this registrational trial, noted July 22, 2024.",phase,POS,successful
1585,1585_0,"Phase 2 Run-in cohort enrollment completed, noted July 22, 2024.","phase,enrollment",POS,enrollment completed
1586,1586_0,"Phase 2 Run-in cohort enrollment completed, noted July 22, 2024.","phase,enrollment",POS,enrollment completed
1587,1587_0,"Phase 3 study did not meet its primary endpoint, noted July 23, 2023.","endpoint,phase",NEG,did not meet
1589,1589_0,"Phase 2 dosing initiated, noted July 23, 2024.","phase,clinical",POS,dosing initiated
1590,1590_0,"Phase 2b/3 study met its primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150, noted July 23, 2024.","safety,phase",POS,met
1591,1591_0,"IND cleared by the FDA for collaborator Moffitt Cancer Center, noted July 23, 2024.",regulatory,POS,cleared by the FDA
1592,1592_0,"Phase 2 enrollment completed, noted July 23, 2024.","phase,enrollment",POS,enrollment completed
1599,1599_0,"Fast Track Designation (FTD) granted by the FDA, noted July 23, 2024.",regulatory,POS,Fast Track
1601,1601_0,"Phase 3 data met its primary and key secondary objectives of superiority compared to prophylaxis, noted on July 24, 2024.","phase,financial",POS,met
1602,1602_0,"Fast track designation granted by the FDA, noted July 24, 2024.",regulatory,POS,Fast track
1603,1603_0,"Phase 3 study dosing initiated, noted July 24, 2024.","phase,clinical",POS,dosing initiated
1604,1604_0,"Phase 3 study dosing initiated, noted July 24, 2024.","phase,clinical",POS,dosing initiated
1605,1605_0,"Phase 2b topline data did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor, noted July 24, 2025.","endpoint,phase,clinical",POS,statistically significant
1606,1606_0,"Phase 2b topline data did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor, noted July 24, 2025.","endpoint,phase,clinical",POS,statistically significant
1608,1608_0,"Phase 1b/2a unblinded safety data indicated that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine response, noted July 24, 2024.","safety,phase",POS,well-tolerated
1609,1609_0,"FDA supplemental Approval on July 24, 2024.",regulatory,POS,Approval
1614,1614_0,"Fast Track designation granted by the FDA, noted July 25, 2024.",regulatory,POS,Fast Track
1615,1615_0,"Fast Track designation granted by the FDA, noted July 25, 2024.",regulatory,POS,Fast Track
1616,1616_0,"FDA Approval of label expansion on patients 12 months and older, noted July 25, 2024.",regulatory,POS,FDA Approval
1617,1617_0,"Phase 2 topline 15-week data met its primary safety and tolerability endpoint and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across multiple disease-related secondary","safety,phase,financial",POS,met
1622,1622_0,"IND cleared by the FDA, noted July 25, 2024.",regulatory,POS,cleared by the FDA
1624,1624_0,"Phase 3 data met all primary and secondary pharmacokinetic endpoints, study expected to be completed by late 3Q / early 4Q 2024.","phase,financial",POS,met
1624,1624_1,"NDA filing expected 4Q 2024/ early 1Q 2025, noted July 25, 2024.",regulatory,POS,NDA filing
1627,1627_0,"FDA Oncologic Drugs Advisory Committee (ODAC) acknowledged that treatment met the primary endpoint of event-free survival (EFS), noted July 25, 2024.",endpoint,POS,met
1628,1628_0,"Phase 1/2 trial FDA granted Orphan drug designation and Rare Pediatric Disease Designation, noted July 25, 2024.","phase,regulatory",POS,FDA granted
1629,1629_0,Phase 1a topline data demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospi,"safety,clinical",POS,favorable safety
1631,1631_0,"Phase 2b topline data met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo, noted July 26, 2024.","endpoint,phase,clinical",POS,met
1632,1632_0,"Phase 3 FDA placed a clinical hold based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin that could not","phase,regulatory",NEG,clinical hold
1633,1633_0,"IND placed on clinical hold, noted July 26, 2024.",regulatory,NEG,clinical hold
1637,1637_0,"Phase 2 data presented at AAIC showed a consistent trend in cognitive improvement compared to placebo across multiple measures, with participants treated for six months demonstrating a 39% slowing of","effect,phase,clinical",POS,data presented at AAIC
1640,1640_0,"Phase 2 trial did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group, noted July 29, 2024.","endpoint,phase",NEG,did not meet
1641,1641_0,"Phase 1 dosing initiated, noted July 29, 2024.","phase,clinical",POS,dosing initiated
1642,1642_0,"Phase 1 dosing initiated, noted July 29, 2024.","phase,clinical",POS,dosing initiated
1643,1643_0,"IND cleared by the FDA, noted July 29, 2024.",regulatory,POS,cleared by the FDA
1644,1644_0,"IND cleared by the FDA, noted July 29, 2024.",regulatory,POS,cleared by the FDA
1646,1646_0,"Phase 2a data presented at AAIC reported that there was a mean 14.1 pg/mL increase in the placebo treatment group (N=13) vs. mean 10.6 pg/mL reduction with neflamapimod treatment, noted July 29, 2024.","sample,phase,clinical",POS,data presented at AAIC
1647,1647_0,"Phase 3 data reported a a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy, noted July 29, 2024.","endpoint,phase",POS,statistically significant
1648,1648_0,"Phase 2 study met its primary endpoint, showing statistically significant and clinically meaningful complete response rates in both dose groups compared to placebo.","endpoint,phase",POS,met
1650,1650_0,"FDA approved via 505(b)(2) pathway, noted July 29, 2024.",regulatory,POS,FDA approved
1651,1651_0,"FDA approved on July 29, 2024.",regulatory,POS,FDA approved
1652,1652_0,"Phase 2 trial met its primary endpoint, noted July 30, 2024.","endpoint,phase",POS,met
1653,1653_0,"Phase 2 trial met its primary endpoint, noted July 30, 2024.","endpoint,phase",POS,met
1654,1654_0,"Phase 2 trial met its primary endpoint, noted July 30, 2024.","endpoint,phase",POS,met
1658,1658_0,"NDA submitted to FDA, noted July 30, 2024.",regulatory,POS,NDA submitted
1659,1659_0,Preclinical new biomarker data to be presented at AAIC showed the ability to reduce Î±-synuclein levels in cerebrospinal fluid.,clinical,POS,data to be presented at AAIC
1662,1662_0,"Phase 2/3 data did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysis, noted July 30, 2024.","endpoint,phase",NEG,did not meet
1663,1663_0,"Phase 3 trial did not meet the primary endpoint of overall survival, noted July 30, 2024.","endpoint,phase",NEG,did not meet
1665,1665_0,"Approved July 31, 2024.",catalyst,POS,Approved
1667,1667_0,"Breakthrough Therapy Designation granted by the FDA, noted July 31, 2024.",regulatory,POS,Breakthrough Therapy
1668,1668_0,"Phase 1/2 trial met primary endpoint, noted July 31, 2024.","endpoint,phase",POS,met
1670,1670_0,"Phase 2 enrollment completed, noted July 31, 2024.","phase,enrollment",POS,enrollment completed
1671,1671_1,"It was well tolerated, without reports of liver enzyme elevation or bleeding events, across once daily doses ranges for 10 days.",safety,POS,well tolerated
1673,1673_0,"Phase 3 data reported that 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% of patients in the placebo arm, noted August 1, 202","endpoint,phase",POS,achieved
1674,1674_0,"Phase 3 data reported a statistically significant improvements in both primary endpoints, noted August 1, 2024.","endpoint,phase",POS,statistically significant
1675,1675_1,"It achieved a statistically significant higher clinical remission rate at week 26 compared to the placebo, noted on August 1, 2024.",catalyst,POS,achieved
1677,1677_0,"Approved August 1, 2024.",catalyst,POS,Approved
1678,1678_0,"NDA resubmitted August 1, 2024.",regulatory,POS,NDA resubmitted
1679,1679_0,"Phase 2 update reported that treatment was well tolerated with no drug-related SAEs and no cases of intraocular inflammation, noted August 1, 2024.","safety,phase",POS,well tolerated
1680,1680_0,"Phase 2 update reported that treatment was well tolerated with no drug-related SAEs and no cases of intraocular inflammation, noted August 1, 2024.","safety,phase",POS,well tolerated
1688,1688_0,"Phase 3 study determined by the FDA that the trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint, noted August 5, 2024.","endpoint,phase,regulatory",POS,statistically significant
1699,1699_0,"Approved August 6, 2024.",catalyst,POS,Approved
1700,1700_0,"Phase 2 data demonstrated stable or improved diabetic retinopathy severity scores (DRSS) and a favorable safety profile at nine-months., noted August 7, 2024.","endpoint,safety,phase",POS,favorable safety
1702,1702_0,"Approved August 7, 2024.",catalyst,POS,Approved
1703,1703_0,"Approved August 8, 2024.",catalyst,POS,Approved
1704,1704_0,"Phase 3 top-line data reported that the trial met its primary endpoint, noted August 8, 2024.","endpoint,phase,clinical",POS,met
1705,1705_0,"Phase 3 trial met primary endpoint, noted August 8, 2024.","endpoint,phase",POS,met
1706,1706_0,"Approved August 8, 2024.",catalyst,POS,Approved
1708,1708_0,"Phase 1 trial met primary endpoint, noted August 8, 2024.","endpoint,phase",POS,met
1709,1709_0,"Phase 2 trial met its primary endpoint, noted August 8, 2024.","endpoint,phase",POS,met
1711,1711_0,"Phase 1/2 5 mg/kg cohort data reported a statistically significant 37% increase in exon 44 skipping and up to 66% skipping with delpacibart zotadirsen 5 mg/kg at four months, noted August 9, 2024.",phase,POS,statistically significant
1712,1712_0,"Approved August 9, 2024.",catalyst,POS,Approved
1715,1715_0,"Phase 3 data reported that ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults â‰¥ 18 years of age, noted August 12, 2024.","safety,phase",POS,well-tolerated
1716,1716_0,"Approved August 12, 2024.",catalyst,POS,Approved
1717,1717_0,"Approved August 12, 2024.",catalyst,POS,Approved
1725,1725_0,"Phase 1b topline data reported that treatment demonstrated a favorable safety profile and was well tolerated, with all adverse events classified as either mild or moderate, and most resolving on the d","safety,phase,clinical",POS,favorable safety
1726,1726_0,"Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted Augus",endpoint,POS,achieved
1730,1730_0,"Phase 2 topline data reported that trial met primary endpoint, noted August 13, 2024.","endpoint,phase,clinical",POS,met
1732,1732_0,"Approved August 14, 2024.",catalyst,POS,Approved
1733,1733_0,"Approved August 14, 2024.",catalyst,POS,Approved
1734,1734_0,"Approved August 14, 2024.",catalyst,POS,Approved
1737,1737_0,"Approved 15, 2024.",catalyst,POS,Approved
1738,1738_0,"Approved 15, 2024.",catalyst,POS,Approved
1739,1739_0,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.","endpoint,phase",POS,met
1740,1740_0,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.","endpoint,phase",POS,met
1741,1741_0,"Phase 3 data reported that that it met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL), noted August 15, 2024.","endpoint,phase",POS,met
1742,1742_0,"Approved August 16, 2024.",catalyst,POS,Approved
1743,1743_0,"Phase 2 data reported that the primary endpoints for this qIRV first-generation candidate were not met in adults aged 65 and older, as statistical non-inferior relative vaccine efficacy (""rVE"") compar","endpoint,phase",POS,met
1744,1744_0,"Tentative approval announced August 19, 2024.",regulatory,POS,approval
1747,1747_0,"Phase 1 dosing initiated, noted August 19, 2024.","phase,clinical",POS,dosing initiated
1751,1751_0,"FDA approved on August 20, 2024.",regulatory,POS,FDA approved
1754,1754_0,"FDA approved under ANDA approval on August 20, 2024.",regulatory,POS,FDA approved
1758,1758_0,"Phase 2 analysis by the IDMC demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, to preserve cash the company is halting the registra","phase,regulatory",POS,approval
1759,1759_0,"CRL announced August 20, 2024.",regulatory,NEG,CRL
1763,1763_0,"Phase 2 dosing initiated, noted August 22, 2024.","phase,clinical",POS,dosing initiated
1764,1764_0,"Approved August 22, 2024.",catalyst,POS,Approved
1765,1765_0,"Phase 3 trial did not meet its primary endpoint, noted August 22, 2024.","endpoint,phase",NEG,did not meet
1766,1766_0,"Approved August 22, 2024.",catalyst,POS,Approved
1767,1767_0,"Approved August 22, 2024.",catalyst,POS,Approved
1770,1770_0,"Trial data reported that treatment was safe and tolerable with significant improvement noted across many aspects of skin appearance, noted August 26, 2024.",clinical,POS,significant improvement
1771,1771_0,"FDA approved on August 26, 2024.",regulatory,POS,FDA approved
1772,1772_1,"At higher oral dose, Ketamir-2 achieved complete normalizat",catalyst,POS,achieved
1773,1773_0,"Phase 2b data published at the Journal of sexual medicine showed that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences.","safety,phase",POS,well tolerated
1774,1774_0,"Phase 3 topline data reported that the trial did not meet its primary endpoint, noted August 27, 2024.","endpoint,phase,clinical",NEG,did not meet
1778,1778_0,"IRB has approved a single and multiple doser study, noted August 27, 2024.",catalyst,POS,approved
1779,1779_0,"Phase 2 met the primary endpoint, showing significant improvement in PANSS scores versus placebo, and was well-tolerated.","endpoint,safety,phase,clinical",POS,met
1779,1779_1,"Secondary endpoints were also met, noted August 28, 2024.","endpoint,financial",POS,met
1781,1781_0,"Phase 3 data reported that the trial met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction, noted August 28, 2024.","endpoint,phase",POS,met
1782,1782_0,Phase 3 data presented at MHSRS highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant improveme,phase,POS,statistically significant
1785,1785_0,"Phase 1 data reported that single and multiple doses of GT-02287 were safe and generally well tolerated up to and including the highest planned dose levels across all age groups, with no discontinuati","safety,phase",POS,well tolerated
1786,1786_0,"BLA submitted August 29, 2024.",regulatory,POS,BLA submitted
1787,1787_0,"FDA final approval on August 29, 2024.",regulatory,POS,approval
1791,1791_0,"Approved August 30, 2024.",catalyst,POS,Approved
1798,1798_0,"NDA submitted to the FDA under 505(b)(2) pathway, noted September 3, 2024",regulatory,POS,NDA submitted
1802,1802_0,"Phase 1/2 topline data reported that at the high and middle doses, VAX-31 met or exceeded the regulatory immunogenicity criteria for all 31 serotypes and, at the low dose, for 29 of 31 serotypes, note","phase,clinical",POS,met
1804,1804_0,"Fast Track Designation granted by the FDA, noted September 3, 2024.",regulatory,POS,Fast Track
1807,1807_0,"Phase 2 trial met its primary endpoint, noted September 3, 2024.","endpoint,phase",POS,met
1809,1809_0,"Phase 2/3 topline data did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23), noted September 3, 2024.","endpoint,phase,financial,clinical",NEG,did not meet
1810,1810_1,"Phase 1 data to dosing initiated, noted Septem","phase,clinical",POS,dosing initiated
1811,1811_0,"Phase 2b trial did not meet its primary or secondary endpoints, noted September 4, 2024.","endpoint,phase,financial",NEG,did not meet
1812,1812_0,"Phase 2/3 data reported statistically significant improvement compared to a prespecified matched sham control group, noted September 4, 2024.","phase,clinical",POS,statistically significant
1813,1813_0,"Phase 2/3 data reported statistically significant improvement compared to a prespecified matched sham control group, noted September 4, 2024.","phase,clinical",POS,statistically significant
1818,1818_0,"Phase 2 study enrollment completed, noted September 4, 2024.","phase,enrollment",POS,enrollment completed
1819,1819_0,"Phase 3 data to be presented at the SSIEM Annual Symposium 2024 showed that study was well tolerated, noted September 5, 2024.","safety,phase",POS,well tolerated
1820,1820_0,"Phase 3 data to be presented at the SSIEM Annual Symposium 2024 showed that study was well tolerated, noted September 5, 2024.","safety,phase",POS,well tolerated
1821,1821_0,"Phase 1b enrollment completed, noted September 5, 2024.","phase,enrollment",POS,enrollment completed
1822,1822_0,"Phase 1/2 FDA granted Fast Track designation, noted September 5, 2024","phase,regulatory",POS,Fast Track
1823,1823_0,"Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin glargine at week 52, noted September 5, 2024.","endpoint,phase,clinical",POS,met
1824,1824_0,"Phase 3 topline data reported that the trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 26, noted September 5, 2024.","endpoint,phase,clinical",POS,met
1825,1825_0,"FDA granted orphan drug designation, noted September 5, 2024.",regulatory,POS,FDA granted
1826,1826_0,"Phase 2a data from study showed that during this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptom",phase,POS,successful
1829,1829_0,"Approved September 5, 2024.",catalyst,POS,Approved
1830,1830_0,"Approved September 5, 2024.",catalyst,POS,Approved
1834,1834_0,"Phase 3 data reported that it met its primary endpoint with the addition of Nucala to inhaled maintenance therapy, noted September 6, 2024.","endpoint,phase",POS,met
1835,1835_0,"BLA submission completed, noted September 6, 2024.",regulatory,POS,BLA submission
1839,1839_0,"Additional Phase 3 data presented at WCLC reported a hazard ratio (HR) of 0.51, and a clinically meaningful benefit was demonstrated across clinical subgroups, noted September 8, 2024.","phase,clinical",POS,data presented at WCLC
1846,1846_0,"Phase 2 patient dosing initiated, noted September 9, 2024.","phase,clinical",POS,dosing initiated
1847,1847_0,"Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE) and the 12-month OS rate was 80%, noted September 9, 2024.","endpoint,phase,clinical",POS,data presented at ESMO
1848,1848_0,"Phase 1 update reported that two patients with recurrent /refractory EWS are experiencing ongoing complete responses (CR), two patients achieved stable disease (SD), and two patients withdrew from the","endpoint,phase",POS,achieved
1849,1849_0,"Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.","phase,clinical",POS,data presented at ESMO
1850,1850_0,"Phase 1 data presented at ESMO reported partial responses, tumor shrinkage and prolonged stable disease, noted September 9, 2024.","phase,clinical",POS,data presented at ESMO
1854,1854_0,"Phase 1 dosing initiated, noted September 9, 2024.","phase,clinical",POS,dosing initiated
1858,1858_0,"Phase 1b data presented at WCLC showed an 81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases, noted September 9, 2024.","endpoint,phase,clinical",POS,data presented at WCLC
1862,1862_0,"Phase 1b/2a study data presented at the European Respiratory Society (ERS) Congress reported that treatment was well tolerated and no adverse events of special interest, noted September 9, 2024.","safety,phase",POS,well tolerated
1864,1864_0,"Phase 3 data presented at EASD efsitora met the primary endpoint of non-inferior A1C reduction at week 26, noted September 9, 2024.","endpoint,phase",POS,met
1866,1866_0,"Phase 1 dose escalation data presented at ESMO reported that 1 pt had an unconfirmed partial response (uPR) and 7/14 (50%) efficacy evaluable pts had a best response of stable disease or better, noted","phase,clinical",POS,data presented at ESMO
1871,1871_0,"Phase 1 data presented at ESMO reported that 7 pts had 9 â‰¥ Gr 3 AEs assessed as potentially related to CVGBM, noted September 9, 2024.","safety,phase,clinical",POS,data presented at ESMO
1872,1872_0,"Phase 1 data reported a statistically significant mean weight loss up to 5.5% over 28 days, noted September 9, 2024.",phase,POS,statistically significant
1874,1874_0,"Phase 3 Outcomes study dosing initiated, noted September 9, 2024.","phase,clinical",POS,dosing initiated
1875,1875_0,"Phase 3 Outcomes study dosing initiated, noted September 9, 2024.","phase,clinical",POS,dosing initiated
1882,1882_0,"Phase 3 data presented at Webcast achieved all primary and secondary endpoints, noted September 10, 2024.","endpoint,phase,financial",POS,achieved
1884,1884_0,"Phase 1 study showed a favorable safety profile with no on-target adverse events commonly associated with other OX2R agonists, such as hepatotoxicity or visual disturbances.","safety,phase",POS,favorable safety
1888,1888_0,"FDA Granted RMAT designation, noted September 10, 2024.",regulatory,POS,FDA Granted
1889,1889_1,The therapy was well-tolerated with no treatment-related serious adv,safety,POS,well-tolerated
1893,1893_0,"Phase 2a FDA granted Orphan drug designation, noted Septemeber 11, 2024.","phase,regulatory",POS,FDA granted
1894,1894_0,"Phase 3 met its primary and secondary endpoints, noted September 11, 2024.","endpoint,phase,financial",POS,met
1895,1895_0,"Phase 1/2 trial did not meet the study's primary efficacy objective, noted September 11, 2024.",phase,NEG,did not meet
1896,1896_0,"Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.","endpoint,phase,financial",POS,met
1897,1897_0,"Phase 3 met its primary and key secondary endpoints, noted September 11, 2024.","endpoint,phase,financial",POS,met
1898,1898_0,"Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.","endpoint,phase,financial",POS,met
1899,1899_0,"Phase 3 trial met its primary and key secondary endpoints, noted September 11, 2024.","endpoint,phase,financial",POS,met
1903,1903_0,"Approved September 11, 2024.",catalyst,POS,Approved
1904,1904_0,"Approved September 11, 2024.",catalyst,POS,Approved
1907,1907_0,"Phase 3 trial study failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48, study did not meet primary endpoint.","endpoint,phase",NEG,did not meet
1908,1908_0,"Phase 3 trial study failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48, study did not meet primary endpoint.","endpoint,phase",NEG,did not meet
1916,1916_0,"Phase 1a pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood, study was generally well tolerated with no drug-related adverse events, noted September 12, 2024.",safety,POS,well tolerated
1917,1917_0,"Phase 3 enrollment completed, noted September 12, 2024.","phase,enrollment",POS,enrollment completed
1918,1918_0,"Phase 1 data from ESMO noted that treatment was safe and well-tolerated with preliminary signals of monotherapy antitumor activity, noted September 12, 2024.","safety,phase",POS,well-tolerated
1919,1919_0,"Phase 2 trial failed to meet its primary endpoint, noted September 12, 2024.","endpoint,phase",NEG,failed to meet
1921,1921_0,"Approved September 12, 2024.",catalyst,POS,Approved
1923,1923_0,"Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr","endpoint,sample,phase,clinical",POS,data presented at ESMO
1924,1924_0,"Phase 1 data presented at ESMO showed signs of anti-tumor activity, including partial responses in 3 of 26 patients with heavily pre-treated NSCLC or esophageal cancer, and additional patients with pr","endpoint,sample,phase,clinical",POS,data presented at ESMO
1925,1925_0,"FDA approval on September 13, 2024.",regulatory,POS,FDA approval
1926,1926_0,"FDA approved on September 13, 2024.",regulatory,POS,FDA approved
1927,1927_0,"Approved September 13, 2024.",catalyst,POS,Approved
1928,1928_0,"Phase 1 dose escalation data presented at ESMO showed it was well-tolerated across all doses with no dose-limiting toxicities and achieved dose-proportional pharmacokinetics, noted September 13, 2024.","safety,phase,clinical",POS,achieved
1929,1929_0,"Phase 1 data presented at ESMO reported that treatment was generally well tolerated with no unexpected adverse events, and encouraging antitumor activity, noted September 13, 2023.","safety,phase,clinical",POS,well tolerated
1936,1936_0,"Phase 1/2 preliminary safety, efficacy, and quality of life outcomes at ESOPRS reported that patients in cohort 1 (40 mg Q3W) achieved early clinical responses across manifestations of disease, noted","safety,phase",POS,achieved
1937,1937_0,"Phase 1b/2 data from ESMO showed a manageable safety profile and encouraging efficacy in patients with heavily pretreated HR+/HER2- breast cancer, noted September 14, 2024.","safety,phase",POS,manageable safety
1941,1941_0,"Phase 2 data from ESMO reported that treatment with ozuriftamab vedotin achieved durable responses and promising tumor control among a patient population with a median of 3 prior lines of therapy, not",phase,POS,achieved
1949,1949_0,"Phase 1b data presented at ESMO reported that 30 pts had confirmed partial responses, with an overall response rate of 75%, noted September 15, 2024.","phase,clinical",POS,data presented at ESMO
1951,1951_0,"Additional Phase 2b data presented at ESMO reported that E+P resulted in numerically higher ORR & DCR compared to P only in CPS â‰¥1 pts noted September 15, 2024.","endpoint,phase,clinical",POS,data presented at ESMO
1953,1953_0,"Phase 2 clinical hold lifted by the FDA, noted September 16, 2024.","phase,regulatory",NEG,clinical hold
1955,1955_0,"Phase 2 clinical hold lifted by the FDA, noted September 16, 2024.","phase,regulatory",NEG,clinical hold
1957,1957_0,"Phase 1/2 data from ESMO reported a 45% overall response rate (ORR), 11.1 months median duration of response and a generally well-tolerated safety profile, noted September 16, 2024.","endpoint,safety,phase",POS,well-tolerated
1958,1958_0,"Phase 1/2 data from ESMO reported that 75% of patients achieved disease control, including two patients who achieved Partial Responses, noted September 16, 2024.",phase,POS,achieved
1959,1959_0,"Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not","endpoint,sample,phase,clinical",POS,data presented at ESMO
1960,1960_0,"Phase 2 data presented at ESMO 24 showed a 69% overall response rate (ORR), with tumor reductions in 15 out of 16 patients and a 79% rate of targeted immune responses to the vaccine's neoantigens, not","endpoint,sample,phase,clinical",POS,data presented at ESMO
1962,1962_0,"Phase 1/2 data to be presented at ISFTD showed sustained increases in cerebrospinal fluid (CSF) progranulin levels in all treated patients for up to 12 months, with no serious adverse events observed","safety,phase",NEG,serious adverse events
1964,1964_0,"Phase 1/2 initial clinical results presented at ESMO 2024 showed anti-tumor responses in 29% (4/14) of efficacy-evaluable, heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) wh","phase,clinical",POS,results presented at ESMO
1965,1965_0,"Phase 3 topline data presented at ESMO demonstrated a significant increase in annualized growth velocity (AGV) compared to placebo, with an LS mean treatment difference of 1.49 cm/year at Week 52.","effect,phase,clinical",POS,data presented at ESMO
1968,1968_0,"Phase 3 study presented data shared at ESMO demonstrated a substantial reduction in Grade 4 neutropenia (over 80% reduction) and a favorable safety profile, with fewer serious adverse events and impro","safety,phase",NEU,favorable safety
1970,1970_0,"Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon","endpoint,phase",POS,achieved
1971,1971_0,"Phase 2 data from the 303 Study at ESMO 2024 showed that among 19 evaluable patients, the combination achieved a 21.1% overall response rate (ORR), a median progression-free survival (PFS) of 8.63 mon","endpoint,phase",POS,achieved
1972,1972_0,"Phase 3 final analysis of OS showed a numerical but not statistically significant improvement favoring cabozantinib in combination with atezolizumab, noted September 16, 2024.","endpoint,phase,clinical",NEU,statistically significant
1983,1983_0,"Phase 2 full data presented at ESMO reported that the median OS was 30 months (95% CI 18.4, NE), ORR of 36% and the 12-month OS rate was 77%, noted September 16, 2024.","endpoint,phase,clinical",POS,data presented at ESMO
1984,1984_0,"Phase 1b/2 data presented at ESMO showed clinical activity in hard-to-treat cancers, including ovarian cancer and immune checkpoint inhibitor (ICI)-naÃ¯ve and refractory microsatellite stable (MSS)/mic","phase,clinical",POS,data presented at ESMO
1985,1985_0,"Phase 1 study determined the recommended Phase 2 dose to be 8-12 mg/kg, with givastomig being well-tolerated up to the highest study doses.","safety,phase",POS,well-tolerated
1986,1986_0,"Phase 3 data presented at ESMO reported that ORR was 72.6% vs 60.1% with pembro + SOC vs pbo + SOC, noted September 16, 2024.","endpoint,phase,clinical",POS,data presented at ESMO
1987,1987_0,"Phase 2 data presented at ESMO showed a confirmed objective response rate (cORR) of 84%, a median duration of response (DoR) of 18.7 months, a median progression-free survival (mPFS) of 15.2 months, a","endpoint,phase,clinical",POS,data presented at ESMO
1988,1988_0,Phase 3 data reported a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatme,phase,POS,statistically significant
1989,1989_0,"Phase 1 partial clinical hold removed by the FDA, noted September 17, 2024.","phase,regulatory",NEG,partial clinical hold
1991,1991_0,"Phase 2 enrollment completed, noted September 17, 2024","phase,enrollment",POS,enrollment completed
1992,1992_0,"Phase 1 dosing initiated September 17, 2024.","phase,clinical",POS,dosing initiated
1994,1994_0,"Phase 2a trial dosing initiated, noted September 17, 2024.","phase,clinical",POS,dosing initiated
1997,1997_0,"FDA Approved on September 17, 2024.",regulatory,POS,FDA Approved
2000,2000_0,"FDA Approved on September 18, 2024.",regulatory,POS,FDA Approved
2001,2001_0,"Phase 3b additional data presented at ECTRIMS showed that 30-minute BRIUMVI infusions were well-tolerated, with only mild (Grade 1) infusion-related reactions, and patients switching from prior anti-","safety,phase",POS,well-tolerated
2002,2002_0,"FDA granted Expanded Access Policy (EAP), noted September 18, 2024.",regulatory,POS,FDA granted
2004,2004_0,"CRL issued by the FDA on September 18, 2024.",regulatory,NEG,CRL
2008,2008_0,"Phase 2a topline data reported that the trial met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFF, noted September 19, 2024.","endpoint,phase,clinical",POS,met
2009,2009_0,"Approved September 19, 2024.",catalyst,POS,Approved
2010,2010_0,"Approved September 20, 2024.",catalyst,POS,Approved
2011,2011_0,"Phase 2a trial data reported that all doses of monlunabant achieved a statistically significant weight loss compared to placebo, noted September 20, 2024.",phase,POS,achieved
2012,2012_0,"Approved September 20, 2024.",catalyst,POS,Approved
2013,2013_0,"Approval announced September 20, 2024.",regulatory,POS,Approval
2014,2014_0,"Additional Phase 3 data reported that statistically significant mean differences in the change in PANSS total scores from baseline to week 8 of -9.71 points, -11.25 points, and -9.69 points versus pla",phase,POS,statistically significant
2016,2016_0,"Phase 2 results showed that a 200 mg daily dose was selected for pivotal development, demonstrating a favorable safety profile and a 42% objective response rate (ORR) in 19 evaluable patients, noted S","endpoint,safety,phase",POS,favorable safety
2018,2018_0,"Phase 3 trial did not meet its primary endpoint, noted September 23, 2024.","endpoint,phase",NEG,did not meet
2020,2020_0,"Phase 3 study achieved the primary endpoint and showed statistically significant improvements on the f-SARA at years 1 and 2 , noted September 23, 2024.","endpoint,phase",POS,achieved
2023,2023_0,"Phase 1a interim data reported that treatment was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days, noted September 23, 2024.",safety,POS,well-tolerated
2024,2024_0,"IND Cleared by the FDA, noted September 23, 2024.",regulatory,POS,Cleared by the FDA
2025,2025_0,"Phase 3 trial met its primary endpoint, noted September 24, 2024.","endpoint,phase",POS,met
2027,2027_0,"Phase 2a initial results reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with encouraging findings: The treatment was well tolerated and had no unpl","safety,phase",POS,well tolerated
2028,2028_0,"Preclinical data showed that monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm, noted September 24, 2024.",catalyst,POS,statistically significant
2030,2030_0,"Phase 1a was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship, noted September 24, 2024.",safety,POS,well-tolerated
2034,2034_0,"Phase 3 HOPE-3 clinical trial to combine Cohorts A and B, study planned to serve as a post-approval study and does not intend to unblind Cohort A at this time, which was expected to occur in the 4Q 20","phase,regulatory",POS,approval
2035,2035_0,"Phase 3 trial did not meet its primary endpoint, noted September 25, 2024.","endpoint,phase",NEG,did not meet
2039,2039_0,"Approved September 25, 2024.",catalyst,POS,Approved
2041,2041_0,"Type A Meeting requested to FDA regarding clinical hold after new financing, noted September 25, 2024.",regulatory,NEG,clinical hold
2042,2042_0,"Phase 2 52-week results from EADV reported that 71% of patients (150 mg Q4W) achieved complete response at Week 52, noted September 25, 2024.",phase,POS,achieved
2043,2043_0,"Preclinical data reported a synergistic and statistically significant reduction of several cytokines (TNF-alpha, IL-17, IL-6, IFN-gamma) in the blood compared to each treatment alone, noted September",catalyst,POS,statistically significant
2046,2046_0,"Approved September 26, 2024.",catalyst,POS,Approved
2047,2047_0,"FDA Approved on September 26, 2024.",regulatory,POS,FDA Approved
2050,2050_0,"Phase 2a topline data reported that trial met its primary and secondary endpoints, noted September 26, 2024.","endpoint,phase,financial,clinical",POS,met
2052,2052_0,"Phase 3 trial data reported that trial met its primary endpoint, noted September 26, 2024.","endpoint,phase",POS,met
2054,2054_0,"Clinical hold lifted September 26, 2024.",regulatory,NEG,Clinical hold
2055,2055_0,"Clinical hold lifted September 26, 2024",regulatory,NEG,Clinical hold
2056,2056_0,"Approved September 27, 2024.",catalyst,POS,Approved
2057,2057_0,"Approved September 27, 2024.",catalyst,POS,Approved
2059,2059_0,"Phase 2 28-week data presented at EADV 2024 show ESK-001 was generally well tolerated, and most patients treated with the top dose of 40 mg twice daily achieved PASI 75, noted September 27, 2024.","safety,phase",POS,achieved
2060,2060_0,"FDA granted Expanded Access Program (EAP), noted September 27, 2024.",regulatory,POS,FDA granted
2061,2061_0,"Approved September 27, 2024.",catalyst,POS,Approved
2062,2062_0,"Phase 1/2 first patient achieved a complete response (CR) one month after receiving dose, noted September 27, 2024.","endpoint,phase",POS,achieved
2065,2065_0,"BLA submitted to the FDA, and it was noted on September 27, 2024.",regulatory,POS,BLA submitted
2066,2066_0,"FDA Approved on September 27, 2024.",regulatory,POS,FDA Approved
2067,2067_0,"FDA Approved on September 27, 2024.",regulatory,POS,FDA Approved
2070,2070_1,The drug was well tolerated with no serious adverse e,safety,POS,well tolerated
2072,2072_0,"Phase 2 enrollment completed, noted September 30, 2024.","phase,enrollment",POS,enrollment completed
2073,2073_0,"Phase 2 enrollment completed, noted September 30, 2024.","phase,enrollment",POS,enrollment completed
2075,2075_0,"Phase 3 study dosing initiated, noted September 30, 2024.","phase,clinical",POS,dosing initiated
2077,2077_0,"Phase 3 study dosing initiated, noted September 30, 2024.","phase,clinical",POS,dosing initiated
2078,2078_0,"Phase 3 study dosing initiated, noted September 30, 2024.","phase,clinical",POS,dosing initiated
2087,2087_0,"Fast track designation granted by FDA, noted October 1, 2024.",regulatory,POS,Fast track
2088,2088_0,"FDA granted Breakthrough Therapy designation, noted October 1, 2024.",regulatory,POS,Breakthrough Therapy
2089,2089_0,"Phase 2b data from CNS reported a statistically significant reduction in tumor volume rate change was seen in tumors receiving > 100 Gy absorbed dose, noted October 1, 2024.",phase,POS,statistically significant
2093,2093_1,"Notably, 88% of patients achieved a complete metabolic r",catalyst,POS,achieved
2094,2094_0,"IND cleared by the FDA, noted October 2, 2024.",regulatory,POS,cleared by the FDA
2095,2095_0,Additional Phase 1b/2a data from post hoc analysis emonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs su,phase,POS,statistically significant
2096,2096_0,"Phase 3 trial dosing initiated, noted October 2, 2024.","phase,clinical",POS,dosing initiated
2099,2099_0,"Approved October 3, 2024.",catalyst,POS,Approved
2101,2101_0,"Phase 3 partial clinical hold removed by the FDA, noted October 3, 2024.","phase,regulatory",NEG,partial clinical hold
2106,2106_0,"Approved October 4, 2024.",catalyst,POS,Approved
2109,2109_0,"Phase 2b IND placed on clinical hold, noted October 4, 2024.","phase,regulatory",NEG,clinical hold
2111,2111_0,"Phase 3 study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor function, as measured by the Hammersmith Functional Motor Scale Expande","endpoint,phase",POS,met
2112,2112_0,"Breakthrough Therapy Designation granted by the FDA, noted October 7, 2024.",regulatory,POS,Breakthrough Therapy
2114,2114_0,"Approved October 7, 2024.",catalyst,POS,Approved
2115,2115_0,"Phase 1 data demonstrated a favorable safety profile with no dose-limiting toxicities, noted October 7, 2024.","safety,phase",POS,favorable safety
2117,2117_0,"Preclinical data from the Oligonucleotide Therapeutics Society reported that treatment achieved AAT levels between MM and MZ in rodents as early as Week 1, noted October 7, 2024.",catalyst,POS,achieved
2118,2118_0,"Phase 3 trial met primary endpoint, noted October 7, 2024.","endpoint,phase",POS,met
2119,2119_0,"Phase 3 trial met its primary endpoint, noted October 8, 2024.","endpoint,phase",POS,met
2120,2120_0,"Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n","endpoint,phase,clinical",POS,statistically significant
2121,2121_0,"Phase 2 topline data reported that the trial did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the primary endpoint, n","endpoint,phase,clinical",POS,statistically significant
2128,2128_0,"Phase 3 trial met pre-specified endpoint for two different FA long-term extension studie with highly statistically significant evidence of durable treatment benefit on disease progression, noted Octob",phase,POS,met
2130,2130_0,"Phase 3 additional data presented at CHEST 2024 showed that treatment was well-tolerated, noted October 8, 2024.","safety,phase",POS,well-tolerated
2131,2131_0,"FDA biosimilar approved on October 8, 2024.",catalyst,POS,approved
2132,2132_0,"Phase 3 data presented at CHEST showed that trial met primary endpoint, noted October 8, 2024.","endpoint,phase",POS,met
2133,2133_0,Phase 2b with topline data reported that the trial achieved both its primary and secondary outcomes.,"phase,financial,clinical",POS,achieved
2134,2134_0,"Clinical hold lifted October 9, 2024.",regulatory,NEG,Clinical hold
2135,2135_0,"IND cleared by the FDA, noted October 9, 2024.",regulatory,POS,cleared by the FDA
2136,2136_0,"Phase 1b results after 28 days of once-daily dosing, treatment shown to be safe and well-tolerated, with significant reductions in very long-chain fatty acids (VLCFAs), key biomarkers of X-ALD, noted","safety,phase",POS,well-tolerated
2137,2137_1,Priority review voucher utilized to accelerate review period,regulatory,POS,Priority review
2139,2139_0,"Breakthrough Therapy Designation granted by the FDA, noted October 9, 2024.",regulatory,POS,Breakthrough Therapy
2142,2142_0,"Phase 3 study met primary and all secondary efficacy endpoints, noted October 9, 2024.","phase,financial",POS,met
2148,2148_0,"FDA Approved on October 10, 2024.",regulatory,POS,FDA Approved
2149,2149_0,"FDA Approved on October 10, 2024.",regulatory,POS,FDA Approved
2154,2154_0,"Phase 2b study showed 36% of patients on denifanstat achieved MASH resolution without worsening fibrosis, and 52% had a â‰¥2-point NAS reduction.",phase,POS,achieved
2154,2154_1,"With secondary endpoints and a favorable safety profile,","endpoint,safety,financial",POS,favorable safety
2158,2158_0,"Approved October 11, 2024.",catalyst,POS,Approved
2160,2160_0,"Phase 3 1-year data reported that a greater number of patients that achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075), not","pvalue,phase",POS,achieved
2161,2161_0,"Phase 3 data reported that trial met primary endpoint, noted October 14, 2024.","endpoint,phase",POS,met
2163,2163_0,"IRB approval on US clinical sites for part A of Phase 1/2a, noted October 14, 2024.","phase,regulatory",POS,approval
2165,2165_0,"Phase 3 trial met its primary endpoint, noted October 15, 2024.","endpoint,phase",POS,met
2166,2166_1,"During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD","phase,regulatory",POS,FDA granted
2169,2169_0,"Phase 1 met its primary endpoint, noted October 15, 2024.","endpoint,phase",POS,met
2170,2170_0,"FDA approved by the FDA, noted October 15, 2024.",regulatory,POS,FDA approved
2171,2171_0,"FDA approved by the FDA, noted October 15, 2024.",regulatory,POS,FDA approved
2172,2172_0,"Phase 1 portion to continue following review from safety review committee approval to advance to highest dose, noted October 15, 2024.","safety,phase,regulatory",POS,approval
2173,2173_0,"Phase 3 topline data demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review f","endpoint,phase,clinical",POS,statistically significant
2177,2177_0,"Phase 2 interim data from ID week reported that treatment was well-tolerated and immunogenic against both RSV and hMPV in older adults 60 to 85 years of age, noted October 16, 2024.","safety,phase",POS,well-tolerated
2179,2179_0,"IND Cleared by the FDA, noted October 16, 2024.",regulatory,POS,Cleared by the FDA
2184,2184_0,"Second Phase 3 trial met primary endpoint, noted October 16, 2024.","endpoint,phase",POS,met
2187,2187_0,"Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes.","endpoint,phase",POS,met
2188,2188_0,"Phase 3 data at the NCS showed that the trial met one of its two co-primary endpoints, with 80% of patients achieving SE cessation within 30 minutes.","endpoint,phase",POS,met
2189,2189_0,"Phase 1 data reported that patient #3 has achieved 13 months OS to date, with six months progression free survival (PFS).","endpoint,phase",POS,achieved
2189,2189_1,Patient #4 has not progressed and achieved 12 months PFS and 12 months OS to d,endpoint,POS,achieved
2194,2194_0,"Approved October 17, 2024.",catalyst,POS,Approved
2198,2198_0,"Approved October 17, 2024.",catalyst,POS,Approved
2199,2199_0,"Phase 2b IND placed on clinical hold, noted October 4, 2024.","phase,regulatory",NEG,clinical hold
2199,2199_1,"Phase 2b will be discontinued after clinical hold following the recommendation of the IDMC after its assessment of four Grade 5 (fatal), no","phase,regulatory",NEG,clinical hold
2201,2201_0,"Approved October 18, 2024.",catalyst,POS,Approved
2202,2202_0,"Phase 3 extension data reported that 88% of EYLEA HD patients had a last assigned dosing interval of â‰¥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 w",phase,POS,achieved
2204,2204_0,"Approved October 21, 2024.",catalyst,POS,Approved
2206,2206_0,"Phase 3 data published at the Journal of Surgery trial showed that despite study did not meet its primary endpoint due to COVID-19-related impacts, pre-specified and post-hoc analyses indicated poten","endpoint,phase",NEG,did not meet
2207,2207_0,"Preclinical data reported statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model, noted October 21, 2024.",catalyst,POS,statistically significant
2209,2209_0,"Preclinical data has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica), noted October 21, 2024.",catalyst,POS,approved
2210,2210_0,"Trial data reported that trial met its primary endpoint, noted October 21, 2024.",endpoint,POS,met
2213,2213_0,"Fast Track Designation graned by the FDA, noted October 21, 2024.",regulatory,POS,Fast Track
2214,2214_0,"NDA Approved by the FDA, noted October 21, 2024.",regulatory,POS,Approved
2215,2215_0,"Phase 3 enrollment completed, noted October 21, 2024.","phase,enrollment",POS,enrollment completed
2216,2216_0,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.","safety,phase",POS,well-tolerated
2217,2217_0,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.","safety,phase",POS,well-tolerated
2218,2218_0,"Phase 1/2a long-term results reported that treatment was well-tolerated with 78% of patiences injection-free and 97% reduction in anti-VEGF treatment burden, noted October 21, 2024.","safety,phase",POS,well-tolerated
2220,2220_0,"Phase 1/2 DSMB convened and approved enrollment for the second phase, noted October 21, 2024.",phase,POS,approved
2221,2221_0,"Phase 2 final results reported no SAEs and that all subjects challenged had ETEC negative stool at discharge, noted October 22, 2024.","safety,phase",POS,no SAEs
2222,2222_0,"FDA Biosimilar approval on October 22, 2024.",regulatory,POS,approval
2223,2223_0,"FDA Biosimilar approval on October 22, 2024.",regulatory,POS,approval
2224,2224_0,"Phase 3 trial had positive outcome of the non-binding, interim futility analysis, noted October 22, 2024.",phase,NEG,futility
2230,2230_0,"FDA Approved on October 22, 2024.",regulatory,POS,FDA Approved
2232,2232_0,"Phase 2 dosing initiated, noted October 22, 2024.","phase,clinical",POS,dosing initiated
2246,2246_1,"The Safety Review Committee approved the move after a favorable safety assessment of Cohort 1, with no significant safety issues or dose-limiting toxicities observed, n",safety,POS,favorable safety
2255,2255_0,Phase 2 presented data at the Fall Clinical Dermatology Conference highlighting that approximately 51% of tumors treated in Part 2 achieved complete histological clearance and patients with residual t,phase,POS,achieved
2257,2257_0,"Preclinical data reported that of the eight Study groups reported on today, DehydraTECH-CBD group B and the sole DehydraTECH-liraglutide group H were both successful in reducing blood sugar levels, wh",catalyst,POS,successful
2260,2260_0,"Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.",phase,POS,achieved
2261,2261_0,"Phase 3 data reported that dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status, noted October 24, 2024.",phase,POS,achieved
2264,2264_0,"Phase 3 study did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency, noted October 24, 2024.","endpoint,phase",NEG,did not meet
2266,2266_0,Phase 2 data presentation at ACAAI showed that deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% comp,"effect,phase",POS,achieved
2268,2268_0,"Preclinical data reported that targeted gene insertion can be achieved using ARCUS in greater than 85% of T cells and 39% of non-dividing primary human hepatocytes, noted October 24, 2024.",catalyst,POS,achieved
2276,2276_0,"Phase 1/2 trial dosing initiated, noted November 29, 2022.","phase,clinical",POS,dosing initiated
2276,2276_1,Phase 1/2 data presented at EORTC-NCI-AACR reported that 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response,phase,POS,achieved
2278,2278_0,"Approved October 25, 2025.",catalyst,POS,Approved
2281,2281_0,"Approved October 25, 2024.",catalyst,POS,Approved
2285,2285_0,"Phase 3 data presented at ACAAI reported that patients treated with sebetralstat 300mg (n=49, P=0.002) and sebetralstat 600mg (n=52, P=0.034) achieved a faster reduction in substantial symptom burden","pvalue,sample,phase",POS,achieved
2287,2287_0,Phase 1b/2 data presented at the ACAAI reported rapid inhibition of plasma kallikrein was associated with reductions in HAE attacks and with a favorable safety profile during the first 28 days of the,"safety,phase",POS,favorable safety
2288,2288_0,"Phase 1 preliminary safety data presented at AACR-NCI-EORTC reported acceptable tolerability and encouraging initial antitumor activity, with durability assessment pending longer follow-up, noted Octo","safety,phase,clinical",POS,data presented at AACR
2294,2294_0,"Phase 2 efficacy and safety data from ACAAI reported that trial met all primary end secondary endpoints, noted October 26, 2024.","endpoint,safety,phase,financial",POS,met
2295,2295_0,"Phase 3 study results presented at ASN Kidney Week reported a statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4, noted Octo","pvalue,effect,phase",POS,statistically significant
2300,2300_0,"Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared","pvalue,phase",POS,statistically significant
2301,2301_0,"Phase 3 expanded access data reported a statistically significant difference in favor of debamestrocel (LRT, p= 0.0379) with a median survival time of 46.6 months for the debamestrocel group compared","pvalue,phase",POS,statistically significant
2303,2303_0,"IND cleared by the FDA, noted October 28, 2024.",regulatory,POS,cleared by the FDA
2304,2304_0,"Preclinical data reported that on Day 9, at the optimal dose of 300 mg/kg, Ketamir-2 led to near-complete normalization of pain sensitivity, outperforming FDA-approved gabapentin by 60%, which provide",catalyst,POS,approved
2305,2305_0,"Phase 3 portion of the study enrollment completed, noted October 23, 2024.","phase,enrollment",POS,enrollment completed
2307,2307_0,Phase 3 results reported that a greater number of patients treated with subcutaneous TREMFYA induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI stu,phase,POS,achieved
2308,2308_0,"Phase 3 data reported that 81% of patients maintained long-term clinical remission and 82% achieved long-term endoscopic remission, noted October 28, 2024.",phase,POS,achieved
2313,2313_0,"Phase 1 results presented at ACG Meeting showed no opioid withdrawal effects, reinforcing safety profile, noted October 28, 2024.","safety,phase",NEG,withdrawal
2315,2315_0,"Phase 2 trial met primary and secondary endpoints, noted October 29, 2024.","endpoint,phase,financial",POS,met
2316,2316_0,"Phase 3 trial demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo, noted October 29, 2024.",phase,POS,statistically significant
2317,2317_0,"BLA resubmitted on October 29, 2024.",regulatory,POS,BLA resubmitted
2322,2322_0,Phase 2a data presented at CTAD in late breaking presentation showed that that Lomecel-B's ability to inhibit MMP14 activity correlates with improved clinical and biomarker outcomes in Alzheimer's pat,"phase,clinical",POS,data presented at CTAD
2324,2324_0,"FDA Approved on October 29, 2024.",regulatory,POS,FDA Approved
2325,2325_0,"Phase 2 results presented at CTAD showed a significant slowdown in cognitive decline, particularly in participants with lower plasma p-tau217 levels, an Alzheimerâ€™s biomarker, noted October 29, 2024.","phase,clinical",POS,results presented at CTAD
2326,2326_0,"Phase 2 study did not meet its primary endpoint, based on the planned interim analysis of 16 patients; current development was suspended, noted on October 29, 2024.","endpoint,sample,phase",NEG,did not meet
2329,2329_0,"Phase 1a topline data from 5 cohorts reported that generally well tolerated and achieved concentrations in the cerebrospinal fluid indicating its potential for target engagement in AD patients, noted","safety,clinical",POS,achieved
2330,2330_0,"Phase 3 enrollment completed, noted October 30, 2024.","phase,enrollment",POS,enrollment completed
2335,2335_0,"Phase 3 data reported statistically significant improvements in mean SBP at 22 weeks, noted October 30, 2024.",phase,POS,statistically significant
2338,2338_0,"Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n",partner,NEG,terminated
2339,2339_0,"Trial development ceased as company non-bidding term-sheet terminated following notification from the prospective partner, company looking for potential asset sale to avoid wind-down or dissolution, n",partner,NEG,terminated
2344,2344_0,"Phase 2 study met the primary endpoint at 10mg once daily, noted October 31, 2024.","endpoint,phase",POS,met
2347,2347_0,"Phase 3 data reported primary and secondary endpoints were all highly statistically significant, noted October 31, 2024.","endpoint,phase,financial",POS,statistically significant
2348,2348_0,"Phase 1/2 data presented at CTAD reported that the expression of plasma GFAP and p-tau 217 biomarkers appears to increase predominantly during MCI and that this is inhibited by pepinemab treatment, no","phase,clinical",POS,data presented at CTAD
2352,2352_0,"Phase 3 trial met its primary endpoint, noted November 1, 2024.","endpoint,phase",POS,met
2356,2356_0,"FDA approved on November 4, 2024.",regulatory,POS,FDA approved
2357,2357_0,"FDA approved on November 4, 2024.",regulatory,POS,FDA approved
2363,2363_0,Phase 2a data presented at CTAD confirmed recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB.,"phase,clinical",POS,data presented at CTAD
2364,2364_0,"Preclinical preliminary data from a diet-induced obesity (DIO) model in mice, achieved significant dose-dependent weight loss of up to 16% compared to vehicle, highlighting a novel peripherally-driven",catalyst,POS,achieved
2366,2366_0,"The FDA cleared the Phase 2 trial, noted on November 4, 2024.","phase,regulatory",POS,FDA cleared
2372,2372_0,Preclinical data presented at SITC demonstrated strong anti-tumor activity in multiple CDX and PDX tumor models.,clinical,POS,data presented at SITC
2373,2373_0,"Phase 2 trial showed that patients with acquired hypothalamic obesity who were on therapy for more than one year achieved a mean overall percent reduction in fat mass of 29.6%, versus a reduction in l","phase,partner",POS,achieved
2374,2374_0,"Phase 3 study demonstrated a statistically significant (p=0.0002) longer time to relapse in schizophrenia patients treated with lumateperone compared to placebo, noted November 5, 2024.","pvalue,phase",POS,statistically significant
2376,2376_0,"Phase 1/2 data presented at SITC reported a disease control rates were 86% and 47% for the 200 mg and 100 mg NC410 doses, respectively, noted November 6, 2024.","phase,clinical",POS,data presented at SITC
2377,2377_0,"Phase 3 data presented at ESMO Asia with an overall response was achieved by 81%, noted November 6, 2024.","phase,clinical",POS,achieved
2384,2384_0,"Phase 1 data presented at SITC revealed the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signal, noted November 7, 2024","safety,phase,clinical",POS,data presented at SITC
2386,2386_0,"Preclinical data presented at SITC reported durable disease control in majority of heavily pretreated patients, noted November 7, 2024.",clinical,POS,data presented at SITC
2387,2387_0,"Phase 2 data presented at SITC reported an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately 50% of patients without disease progression at 12 mont","phase,clinical",POS,data presented at SITC
2392,2392_0,Phase 2 data reported at SITC demonstrated statistically significant superiority of the eight-week absolute lymphocyte count with NKTR-255 post chemoradiation and in combination with durvalumab versus,phase,POS,statistically significant
2395,2395_0,"Preclnical PoC data presented at SITC supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only, November 7, 2024.",clinical,POS,data presented at SITC
2396,2396_0,"Phase 3 trial did not meet primary endpoint, noted November 7, 2024.","endpoint,phase",NEG,did not meet
2397,2397_0,"Phase 2 data presented at SITC reported a 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone, noted November 8, 2024.","phase,clinical",POS,data presented at SITC
2400,2400_0,"Phase 1a data presented at SITC reported that the highest three quartiles of T cell responders have not yet reached mDFS, whereas the lowest quartile achieved a mDFS of 3.1 months, noted November 8, 2",clinical,POS,achieved
2401,2401_0,"Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.",phase,POS,statistically significant
2402,2402_0,"Phase 3 data reported a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo, noted November 8, 2024.",phase,POS,statistically significant
2403,2403_0,"Phase 3 trial had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo, noted November 8, 2024.",phase,POS,statistically significant
2409,2409_0,Phase 1 new data presented at SITC showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471,"phase,clinical",POS,data presented at SITC
2410,2410_0,"Phase 1a additional data presented at SITC showed that vaccine was safe and well tolerated by participants in all 3 cohorts, noted November 8, 2024.","safety,clinical",POS,well tolerated
2412,2412_0,"FDA Approved on November 8, 2024.",regulatory,POS,FDA Approved
2417,2417_0,"Preclinical data reported that the combined treatment demonstrated significant improvement in behavioral outcomes related to severe stress-induced conditions as compared to using either agent alone, n",clinical,POS,significant improvement
2418,2418_0,"Phase 1/2 data presented at SITC showed a three-fold increased active (e.g., cleaved) drug exposure in homogenized tumor tissue samples at 10 mg/kg versus a single dose of ipilimumab at 1 mg/kg while","phase,clinical",POS,data presented at SITC
2420,2420_0,"Phase 3 data presented at SITC reported that the median overall survival for the trial has not been reached, however, one-, two-, and three-year survival rates were 75.3%, 63.3%, and 54.8%, respective","phase,clinical",POS,data presented at SITC
2421,2421_0,"Phase 1 data presented at SITC demonstrated durable antitumor activity in heavily pretreated patients with antiâ€“PD-1â€“resistant cancer across multiple cancer types , noted November 9, 2024.","phase,clinical",POS,data presented at SITC
2423,2423_0,"Phase 1 data presented at SITC 2024 reported that a dose range between 8-12 mg/kg Q2W was identified as the preferred dose range for heavily pre-treated GEC patients., noted November 9, 2024.","phase,clinical",POS,data presented at SITC
2424,2424_0,"Phase 1b/2 data presented at SITC reported that OS was greater with zim than with chemo, noted November 9, 2024.","endpoint,phase,clinical",POS,data presented at SITC
2426,2426_0,"Phase 2a dosing initiated, noted November 11, 2024.","phase,clinical",POS,dosing initiated
2431,2431_0,"Phase 2 hold removed, FDA cleared study to begin enrolling in planned Phase 3 trial, noted November 11, 2024.","phase,regulatory",POS,FDA cleared
2433,2433_0,"Phase 2 trial did not meet their primary endpoint, noted November 11, 2024.","endpoint,phase",NEG,did not meet
2434,2434_0,"Phase 1 data presented at SITC indicated that trial endpoints of adequate exposure, safety, tolerability and biological activity were met, noted November 11, 2024.","safety,phase,clinical",POS,met
2435,2435_0,"IRB approval on track as scheduled, company plans new phase of treatment evaluation expected 1Q 2025, noted November 11, 2024.",regulatory,POS,approval
2437,2437_0,"Phase 1 data reported that treatment was well-tolerated with no DLTs and no events of any grade of CRS, ICANS, or GvHD, noted November 11, 2024.","safety,phase",NEU,well-tolerated
2438,2438_0,"Phase 1/2 data reported statistically significant separation between the GTX-102 and sham arms, noted November 11, 2024.",phase,POS,statistically significant
2440,2440_0,"Preclinical data presented at SITC showed robust antigen-mediated expansion, functional persistence, and durable anti-tumor activity in the presence of alloreactive T cells, noted November 11, 2024.",clinical,POS,data presented at SITC
2445,2445_0,Phase 2 topline results showed that the trial met its primary endpoint.,"endpoint,phase,clinical",POS,met
2445,2445_1,"Revumenib demonstrated a favorable safety profile with only 5% treatment-related discontinuation, noted November 12, 2024.",safety,POS,favorable safety
2450,2450_0,"Voluntarily withdrawn November 12, 2024.",catalyst,NEG,withdrawn
2451,2451_0,"BLA submitted November 12, 2024.",regulatory,POS,BLA submitted
2452,2452_0,"108 patients have completed 1-year of treatment which is generally well tolerated to date in patients with acute and stable schizophrenia, noted November 12, 2024.","safety,sample",POS,well tolerated
2454,2454_0,"Phase 1 interim data showed a favorable safety profile and strong pharmacokinetics with a half-life over 90 daysâ€”four times longer than vedolizumab, noted November 12, 2024.","safety,phase",POS,favorable safety
2457,2457_0,"Phase 3 52 week extension data indicated that LYR-210 was generally well tolerated over the extended treatment period, including among patients who received repeat dosing for a total of 12 months.","safety,phase",POS,well tolerated
2465,2465_0,"Approved November 13, 2024.",catalyst,POS,Approved
2466,2466_0,"Approved November 13, 2024.",catalyst,POS,Approved
2467,2467_0,"Additional Phase 3 data reported that the trial met the key secondary endpoint of overall survival (OS), noted November 14, 2024.","endpoint,phase,financial",POS,met
2474,2474_0,"Phase 2 data reported nominally statistically significant improvements in MACrO2 measured from baseline to month 6 in post-hoc analysis, noted November 14, 2024.",phase,POS,statistically significant
2477,2477_0,"Phase 2b data presented at AASLD reported that treatment improved patients' FAST scores but also achieved both MASH resolution and fibrosis improvement, noted November 15, 2024.","phase,clinical",POS,achieved
2478,2478_0,"IND cleared by the FDA, noted November 15, 2024.",regulatory,POS,cleared by the FDA
2479,2479_0,"Phase 2a data presented at AASLD reported that 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1, noted November 15, 2024.","phase,clinical",POS,achieved
2480,2480_0,"Phase 3 data reported that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with LivdelziÂ® (seladelpar) achieved a composite biochemical response, noted November 15, 2",phase,POS,achieved
2482,2482_0,"Phase 1b data presented at AASLD reported that treatment reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after","phase,clinical",POS,data presented at AASLD
2483,2483_0,"Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in",phase,POS,achieved
2484,2484_0,"Phase 2 data reported that 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated in",phase,POS,achieved
2485,2485_0,"FDA approved on November 15, 2024.",regulatory,POS,FDA approved
2486,2486_0,"Phase 3 data presented at ACR Convergence with statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo, noted November 15, 2024.",phase,POS,statistically significant
2489,2489_0,"Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of","phase,clinical",POS,data presented at AASLD
2490,2490_0,"Phase 2b additional 96-Week data presented at AASLD reported an over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of","phase,clinical",POS,data presented at AASLD
2492,2492_0,"Phase 1 additional data from AHA reported mean reductions of greater than 90% from baseline achieved at Day 15 and sustained through at least Day 180, noted November 17, 2024.",phase,POS,achieved
2495,2495_0,"Phase 2a data presented at AASLD reported that 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin, no","phase,clinical",POS,data presented at AASLD
2499,2499_0,"Phase 3 data presented at ACR Convergence demonstrated statistically significant improvement in the primary endpoint of fibromyalgia neoplastic pain and in all six key secondary endpoints, including s","endpoint,phase,financial,clinical",POS,statistically significant
2508,2508_0,"IND cleared by the FDA, noted November 18, 2024.",regulatory,POS,cleared by the FDA
2514,2514_0,"NDA submitted November 18, 2024.",regulatory,POS,NDA submitted
2521,2521_0,"Phase 3 data presented at AHA showed that the trial met its primary endpoint with an LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365, noted November 18, 2024.","endpoint,effect,phase",POS,met
2523,2523_0,"Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.","endpoint,phase",POS,met
2524,2524_0,"Phase 3 study met its co-primary endpoints in patients with moderate to severe plaque psoriasis, noted November 18, 2024.","endpoint,phase",POS,met
2525,2525_0,"Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.","endpoint,phase",POS,met
2526,2526_0,"Phase 3 study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo, noted November 18, 2024.","endpoint,phase",POS,met
2527,2527_0,"Phase 2 enrollment paused, noted November 18, 2024.",phase,NEG,enrollment paused
2530,2530_0,"Phase 2a data presented at AASLD reported a stable ELF score from Week 12 to Week 24, with a reduction in participants with an ELF score of >9.8 at baseline, noted November 18, 2024.","phase,clinical",POS,data presented at AASLD
2534,2534_0,"Phase 2b data presented at AASLD reported rapid and statistically significant reductions in cholestatic pruritus were observed after treatment, noted November 18, 2024.","phase,clinical",POS,statistically significant
2536,2536_0,"Phase 2 study met at the 12-week its primary endpoint, noted November 18, 2024.","endpoint,phase",POS,met
2538,2538_0,"Phase 1b data presenteed at ACR showed patient treated with fludarabine-free conditioning and single-dose FT819; favorable safety profile with no grade â‰¥3 adverse events and no events of CRS, ICANS, o","safety,phase",POS,favorable safety
2539,2539_0,"Phase 1 initial data showed a favorable safety profile, complete responses, and persistence of FT522 live cells, noted November 18, 2024.","safety,phase",POS,favorable safety
2540,2540_0,"Phase 2 data presented at AASLD met the trial's primary endpoint, demonstrating a favorable safety profile over the 15-week treatment period on November 19, 2024.","endpoint,safety,phase,clinical",POS,met
2541,2541_0,"Phase 3 data reported that the trial met its primary endpoint, noted November 19, 2024.","endpoint,phase",POS,met
2543,2543_0,"Phase 3 trial met primary endpoint, noted November 19, 2024.","endpoint,phase",POS,met
2546,2546_0,"Phase 3a data reported that treatment had safe and well-tolerated profile, noted November 19, 2024.",safety,POS,well-tolerated
2547,2547_0,"Phase 2 DSMB review of interim data completed, the DSMB determined that, while the mRNA control arm of the study failed to meet the predetermined primary endpoint, the study should continue enrollment","endpoint,phase",NEG,failed to meet
2549,2549_0,"Phase 2 additional expansion cohort dosing initiated, noted November 19, 2024.","phase,clinical",POS,dosing initiated
2552,2552_0,"Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.","endpoint,phase,financial,clinical",POS,successful
2553,2553_0,"Phase 2b 52 week data presented at AASLD summarized results including successful achievement of study's primary and secondary endpoints, noted November 19, 2024.","endpoint,phase,financial,clinical",POS,successful
2555,2555_0,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.","endpoint,phase,clinical",NEG,did not meet
2556,2556_0,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 20, 2024.","endpoint,phase,clinical",NEG,did not meet
2557,2557_0,"Phase 2/3 data reported that the trial met its primary endpoint, noted November 20, 2024.","endpoint,phase",POS,met
2559,2559_0,"Phase 3 partial topline data indicated that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, noted November 20, 202","phase,clinical",POS,statistically significant
2561,2561_0,"Phase 3 study achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg mon","endpoint,effect,phase",POS,achieved
2562,2562_0,"Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.",phase,POS,achieved
2563,2563_0,"Phase 1b/2a study achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies, noted November 20, 2024.",phase,POS,achieved
2566,2566_0,"Phase 1 preliminary clinical data achieved a confirmed 50% objective response rate (ORR) based on RECIST 1.1 criteria, including one complete response and a disease control rate (DCR) of 100% in six h","endpoint,phase",POS,achieved
2567,2567_1,"This recommendation was based on the absence of any dose limiting toxicities (DLT's),",safety,NEG,DLT
2572,2572_0,"Approved November 21, 2024.",catalyst,POS,Approved
2573,2573_0,"Approved November 21, 2024.",catalyst,POS,Approved
2574,2574_0,"Approved November 21, 2024.",catalyst,POS,Approved
2579,2579_0,"FDA approved on November 22, 2024.",regulatory,POS,FDA approved
2580,2580_0,"FDA approved on November 22, 2024.",regulatory,POS,FDA approved
2583,2583_0,"Phase 3 trial met primary endpoint, noted November 25, 2024.","endpoint,phase",POS,met
2584,2584_0,"Phase 3 trial data demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS), noted November 25, 2024.","endpoint,phase",POS,statistically significant
2587,2587_0,"Phase 3 trial did not meet primary endpoint, noted November 25, 2024.","endpoint,phase",NEG,did not meet
2588,2588_0,"Phase 3 EoP Type C Meeting with the FDA resulted in clear, constructive, and actionable guidance underscoring a pathway to support a future NDA submission, noted November 25, 2024.","phase,regulatory",POS,NDA submission
2593,2593_0,Phase 2 failed to meet primary and secondary endpoints.,"endpoint,phase,financial",NEG,failed to meet
2594,2594_0,Phase 2 failed to meet primary and secondary endpoints.,"endpoint,phase,financial",NEG,failed to meet
2598,2598_0,Phase 2 study failed to meet primary and secondary efficacy endpoints.,"phase,financial",NEG,failed to meet
2599,2599_0,"BLA submitted, noted November 26, 2024.",regulatory,POS,BLA submitted
2601,2601_0,"Phase 2b enrollment completed, noted November 26, 2024.","phase,enrollment",POS,enrollment completed
2602,2602_0,"NORSE EIGHT trial did not meet the SPA primary endpoint, noted November 27, 2024.",endpoint,NEG,did not meet
2605,2605_0,"CRL announced November 27, 2024.",regulatory,NEG,CRL
2608,2608_0,"Phase 1 PK data reported that treatment was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of bi","safety,phase",POS,well-tolerated
2609,2609_0,"Phase 1 initial data reported that 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile, noted December 2,","endpoint,safety,phase",POS,achieved
2610,2610_0,"Phase 3 final data showed that study met its primary endpoint with a statistically significant improvement in overall survival for patients, noted December 2, 2024.","endpoint,phase,clinical",POS,met
2615,2615_0,"FDA Fast track designation granted by the FDA, noted December 2, 2024.",regulatory,POS,Fast track
2616,2616_0,"BLA submission on December 2, 2024.",regulatory,POS,BLA submission
2617,2617_0,"Phase 1a interim update achieved 100% PSA50 declines, 63% PSA90 declines, and 31% PSA99 declines, with durable responses observed at â‰¥12 weeks.",catalyst,POS,achieved
2618,2618_0,"Phase 1b/2a dosing initiated, noted December 2, 2024.","phase,clinical",POS,dosing initiated
2620,2620_0,"Phase 1 dosing initiated, noted December 2, 2024.","phase,clinical",POS,dosing initiated
2623,2623_0,"Fast Track Designation granted by the FDA, noted December 3, 2024.",regulatory,POS,Fast Track
2625,2625_0,Phase 2 data did not meet its primary endpoints.,"endpoint,phase",NEG,did not meet
2627,2627_0,"The phase 1 study showed statistically significant lower ""Drug Liking"" scores for clinical doses of oral nalbuphine (81mg and 162mg) compared to IV butorphanol (6mg), supporting its low abuse potentia",phase,POS,statistically significant
2628,2628_0,"FDA granted Fast Track Designation on December 3, 2024.",regulatory,POS,Fast Track
2630,2630_0,"Phase 1 dosing initiated, noted December 3, 2024.","phase,clinical",POS,dosing initiated
2631,2631_0,"Phase 2 enrollment completed, noted December 3, 2024","phase,enrollment",POS,enrollment completed
2634,2634_0,"Phase 2 data met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12), noted December 4, 2024.","endpoint,safety,phase",POS,met
2637,2637_0,Phase 2b 18-month data showed statistically significant results.,phase,POS,statistically significant
2639,2639_0,"Approved December 5, 2024.",catalyst,POS,Approved
2640,2640_0,"Phase 2 initial data demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients, no","safety,phase",POS,favorable safety
2643,2643_0,"Approved December 5, 2024.",catalyst,POS,Approved
2644,2644_0,"Approved December 5, 2024.",catalyst,POS,Approved
2653,2653_0,Phase 3 OLE long-term safety and efficacy data presented at AES showed that drug achieved 85% sustained monthly seizure reduction at 36 months and one-year seizure freedom in 33% of patients.,"safety,phase",POS,achieved
2657,2657_0,"Phase 2 data presented at ASH reported a clinically significant 2-point decrease on the VAS scale to mild by Week 13 (VAS<4), in SÃ©zary Syndrome Patients, and improvement in Itch intensity from Week 5","phase,clinical",POS,data presented at ASH
2658,2658_0,"Phase 1/2 data presented at ASH reported that all seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction of >60%, noted December 7, 2024.","phase,clinical",POS,achieved
2660,2660_0,"Phase 1/2 escalation data from ASH reported that across all dose levels explored, cemsidomide achieved a 38 percent ORR and 19 percent CMR rate, and in patients with PTCL, cemsidomide achieved a 44 pe","endpoint,phase",POS,achieved
2661,2661_0,"Phase 1b data presented at ASH reported that 68% of baseline nTD patients achieved a hemoglobin increase of â‰¥1.5 g/dL during study period and 50% had sustained increases for â‰¥12 weeks, noted December","phase,clinical",POS,achieved
2662,2662_0,"Preclinical data presented at ASH reported that all NHPs achieved >40% Î³-globin, a key constituent of HbF, post-transplant, noted December 8, 2024.",clinical,POS,achieved
2663,2663_0,"Phase 3 data presented at ASH reported that TRR was achieved by 30.4% (n=52/171) of patients in the mitapivat arm compared to 12.6% (n=11/87) of patients in the placebo arm, noted December 8, 2024.","sample,phase,clinical",POS,achieved
2666,2666_0,"Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted","phase,clinical",POS,data presented at ASH
2667,2667_0,"Phase 2 data presented at ASH reported 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached, noted","phase,clinical",POS,data presented at ASH
2668,2668_0,"Breakthrough Therapy designation (BTD) granted by the FDA, noted December 9, 2024.",regulatory,POS,Breakthrough Therapy
2670,2670_0,"Phase 1a interim data presented at ASH showed 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3, noted December 9, 2024.","endpoint,clinical",POS,data presented at ASH
2671,2671_0,"Phase 3 data reported that trial met its primary endpoint, noted December 9, 2024.","endpoint,phase",POS,met
2673,2673_0,"Phase 2 data presented at ASH included a 56% mean improvement in Total Symptom Score (TSS) at 24 weeks, with 76% of patients achieving a â‰¥50% TSS reduction and 95% of patients with elevated serum tryp","phase,clinical",POS,data presented at ASH
2675,2675_0,"Phase 1/2 preliminary data presented at ASH suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant, noted","phase,clinical",POS,data presented at ASH
2679,2679_0,"Phase 2 data presented at ASH from subgroup analyses (N=64) showed responses across all major subgroups, including heavily pretreated patients, noted December 9, 2024.","sample,phase,clinical",POS,data presented at ASH
2680,2680_0,"Additional Phase 2 data presented at ASH showed best ORR of 97% and CR rate of 77% with 12-month PFS of 95%, data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of","endpoint,phase,clinical",POS,data presented at ASH
2682,2682_0,"Phase 1 topline data in 21 evaluable patients, 48% achieved stable disease at four months, including one partial response with a 45% tumor reduction at the MTD.","phase,clinical",POS,achieved
2682,2682_1,"SON-1010 demonstrated favorable safety,",safety,POS,favorable safety
2683,2683_0,"Phase 3 data reported that 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPROÂ® were progression free at 4.5 years, noted December 9, 2024.",phase,POS,achieved
2685,2685_0,"Additional preclinical data presented at ASH reported that treatment demonstrated intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti",clinical,POS,data presented at ASH
2687,2687_0,"Phase 3 data presented at ASH reported that treatment reduced the risk of disease progression or death by 58% versus standard of care, noted December 9, 2024.","phase,clinical",POS,data presented at ASH
2689,2689_0,"Phase 3 data reported that 96% achieved adequate LDH control (â‰¤1.5 x ULN) across study visits, noted December 9, 2024.",phase,POS,achieved
2690,2690_0,"Phase 1/2 data presented at ASH reported that all 8 of 8 efficacy-evaluable patients responded to treatment (ORR and CRR 100%), noted December 9, 2024.","endpoint,phase,clinical",POS,data presented at ASH
2691,2691_0,"Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.",phase,POS,achieved
2692,2692_0,"Phase 2 trial data reported that 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months, noted December 9, 2024.",phase,POS,achieved
2694,2694_0,"Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.","endpoint,phase,financial",POS,met
2695,2695_0,"Phase 3 data reported that the trial met its primary endpoint of overall survival (OS) and all secondary endpoints, noted December 9, 2024.","endpoint,phase,financial",POS,met
2698,2698_0,"Phase 1 data reported that treatment demonstrated neuroprotective activity through the MET receptor; following siRNA-mediated knockdown of MET, the neuroprotective effects of ATH-1105 on neuronal surv",phase,POS,MET
2700,2700_0,"FDA approved, noted December 9, 2024.",regulatory,POS,FDA approved
2701,2701_0,"Phase 1b data presented at ASH showed that all 3 patients treated in first dose cohort administered fludarabine-free conditioning and show rapid, deep, and sustained B-cell depletion with favorable sa","phase,clinical",POS,data presented at ASH
2703,2703_0,"Phase 1b updated data from investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial, 23 months median Ov","safety,phase",POS,favorable safety
2704,2704_0,"Phase 2 final results presented at ASH showed that 54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and impr","safety,phase,clinical",POS,results presented at ASH
2705,2705_0,"Phase 2 data presented at ASH showed that bitopertin significantly reduced protoporphyrin IX (PPIX) at low and high doses and in both adult and adolescent populations, noted December 9, 2024.","phase,clinical",POS,data presented at ASH
2706,2706_0,"Phase 2 trial updated analysis presented at ASH showed that bitopertin reduced PPIX in all prespecified subgroups across demographic and baseline patient characteristics, noted December 9, 2024.","phase,clinical",POS,analysis presented at ASH
2707,2707_0,"Preliminary data presented at ASH demonstrated that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol, note","safety,clinical",POS,well-tolerated
2708,2708_0,"Phase 1 initial data presented at ASH demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients, RBC-TI/HI-E responses occurred in 40% of evaluable TD patients","phase,clinical",POS,data presented at ASH
2709,2709_0,Additional Phase 1/2 data presented at ASH was well-tolerated and continued to demonstrate a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell t,"safety,phase,clinical",POS,well-tolerated
2710,2710_0,"Preclinical data presented at ASH reported that the mean FVIII activity of months 13-16.5 following LNP dosing was 71%, 7%, and 27% compared to mean FVIII activity of months 3-6 of 76%, 8% and 30%, no",clinical,POS,data presented at ASH
2712,2712_0,"Phase 1/1b data presented at ASH reported that the combination achieved a 99% overall response rate (ORR), noted December 9, 2024.","endpoint,phase,clinical",POS,achieved
2713,2713_0,"Phase 1 data presented at ASH reported an ORR of 94% at the 200mg dose, noted December 9, 2024.","endpoint,phase,clinical",POS,data presented at ASH
2714,2714_0,"Phase 2 data presented at ASH reported that 55.2% (n=48/87) of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, noted December 9, 2024.","sample,phase,clinical",POS,achieved
2715,2715_0,"Phase 1a/1b data presented at ASH reported an 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments, noted December 9, 2024.",clinical,POS,data presented at ASH
2717,2717_0,"Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.","endpoint,phase,clinical",POS,data presented at ASH
2718,2718_0,"Phase 3 data presented at ASH reported an objective response rate (ORR) of 89% and 67% CR rate, noted December 9, 2024.","endpoint,phase,clinical",POS,data presented at ASH
2719,2719_0,"Phase 2 proof of concept results presented at ASH showed that clinical data support Phase 3 enrollment to commence in early 2025, noted December 9, 2024.","phase,clinical",POS,results presented at ASH
2720,2720_0,"Phase 1/2 triplet data presented at ASH reported 10 objective responses (6 CRs, 2 CRi/CRh, and 2 MLFS) among 19 evaluable relapsed/refractory AML patients with FLT3 mutations, treated with the RP2D of","phase,clinical",POS,data presented at ASH
2724,2724_0,"Phase 3 study achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction, noted Decem","endpoint,effect,phase",POS,achieved
2725,2725_0,"Phase 2b topline data did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks, noted December 10, 2024.","endpoint,phase,financial,clinical",POS,statistically significant
2726,2726_0,"Preclinical proof-of-concept achieved for APG777 + APG333 combination with clinical trial planning underway in asthma and COPD patients, noted December 10, 2024.",catalyst,POS,achieved
2727,2727_0,"Phase 1b/2 new data presented at SABCS demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability, noted December 10, 2024","safety,phase,clinical",POS,data presented at SABCS
2729,2729_0,"FDA agreed that data from ongoing Phase 1/2 studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval, no","phase,partner,regulatory",POS,Approval
2730,2730_0,Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug.,"safety,phase",NEU,well tolerated
2731,2731_0,Phase 1/2 results were generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug.,"safety,phase",NEU,well tolerated
2732,2732_0,Phase 1b data presented at ASH continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease a,"endpoint,phase,clinical",POS,data presented at ASH
2733,2733_0,"Phase 3 dosing initiated, noted December 10, 2024.","phase,clinical",POS,dosing initiated
2735,2735_0,"Phase 1b/2a all cohorts enrollment completed December 10, 2024.","phase,enrollment",POS,enrollment completed
2741,2741_0,"Phase 1 data presented at ASH reported that event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0","pvalue,effect,phase,clinical",POS,data presented at ASH
2743,2743_0,"Phase 2b study did not meet its primary endpoint of reducing glucocorticoid (GC) usage, with a placebo-adjusted reduction of only 0.7 mg/day.","endpoint,phase",NEG,did not meet
2745,2745_0,"Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance, noted Decemeber 10, 2024.","endpoint,phase,financial",NEG,did not meet
2746,2746_0,"Phase 1/2 data presented at ASH showed that therapy demonstrated a 94% overall response rate, a favorable safety profile, and no grade 4 cytokine release syndrome or neurotoxicity events, noted Novemb","safety,phase,clinical",POS,favorable safety
2747,2747_0,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.","endpoint,phase,financial,clinical",POS,met
2748,2748_0,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.","endpoint,phase,financial,clinical",POS,met
2749,2749_0,"Phase 3 data presented at ASH showed that trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints, noted December 10, 2024.","endpoint,phase,financial,clinical",POS,met
2750,2750_0,"IND cleared by the FDA, noted December 10, 2024.",regulatory,POS,cleared by the FDA
2751,2751_0,Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w,"phase,clinical",POS,data to be presented at SABCS
2752,2752_0,Phase 1b/2 data to be presented at SABCS suggest that HER2-positive patients whose cancer has been heavily pretreated may benefit from CD47 inhibition via evorpacept's unique mechanism when combined w,"phase,clinical",POS,data to be presented at SABCS
2754,2754_0,"Preclinical data presented at ASH showed that treatment has the potential to be a safe and effective preventative therapeutic using innovative nonclinical models, noted December 10, 2024.",clinical,POS,data presented at ASH
2755,2755_0,"Preclinical data presented at ASH demonstrated that single intravenous injections of RLYB332 to humanized FcRn mice had rapid and sustained effects on pharmacodynamic (PD) parameters, including serum",clinical,POS,data presented at ASH
2759,2759_0,"Phase 3 results for CAN-2409 viral immunotherapy in intermediate-to-high-risk localized prostate cancer, achieved its primary endpoint of significantly improved disease-free survival (DFS) when combin","endpoint,phase",POS,achieved
2765,2765_0,"Phase 1b/2 data results demonstrated reduction in the mean monthly attack rate of 90-95% at 6 months, favorable safety and tolerability profile, noted December 11, 2024.","safety,phase",POS,favorable safety
2766,2766_0,"IND cleared by the FDA, noted December 10, 2024.",regulatory,POS,cleared by the FDA
2774,2774_0,"Phase 2 trial did not meet its primary endpoint, noted December 11, 2024.","endpoint,phase",NEG,did not meet
2775,2775_0,"Phase 2 data showed that the 1 mg dose reduced MBD by 17.3 percentage points, while the 2 mg dose achieved a reduction of 23.5 percentage points, compared to a minimal change in the placebo group of 0","effect,phase",POS,achieved
2777,2777_0,"Phase 3 data presented at SABCS significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations, noted December 11, 2024.","phase,clinical",POS,data presented at SABCS
2781,2781_0,Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500â€“1000,phase,POS,met
2782,2782_0,Phase 2 data from SABCS reported that 50 percent of patients (3/6) in the group that received 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500â€“1000,phase,POS,met
2787,2787_0,"Phase 2b did not meet the primary and secondary endpoints in any of the doses studied in the global, AD trial and all further investment in ANB032 will be discontinued, noted December 12, 2024.","endpoint,phase,financial",NEG,did not meet
2789,2789_0,"Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.",phase,POS,achieved
2790,2790_0,"Phase 1b/2a data reported that 100% of patients achieved remission within 30 days, noted December 12, 2024.",phase,POS,achieved
2797,2797_0,"Phase 1 data reported that no serious adverse events have been reported, noted December 12, 2024.","safety,phase",NEG,serious adverse events
2799,2799_0,"Phase 4 trial met primary endpoint, noted December 12, 2024.",endpoint,POS,met
2800,2800_0,"Data presented at SABCS reported an 60% overall response rate, noted December 12, 2024.",clinical,POS,Data presented at SABCS
2802,2802_0,"Phase 1 trial achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer, noted December 13, 2024.","endpoint,phase",POS,achieved
2803,2803_0,"Approved December 13, 2024.",catalyst,POS,Approved
2804,2804_0,"Approved December 16, 2024.",catalyst,POS,Approved
2805,2805_0,"Approved December 16, 2024.",catalyst,POS,Approved
2807,2807_1,"However, the observed response rate did not meet the Company's thresho",catalyst,NEG,did not meet
2810,2810_0,"Phase 3 dosing initiated, noted December 16, 2024.","phase,clinical",POS,dosing initiated
2812,2812_0,Phase 2 enrollment completed with a registrational trial planned for 2H 2024.,"phase,enrollment",POS,enrollment completed
2814,2814_0,"Phase 2 trial met its primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to dat","endpoint,phase",POS,met
2815,2815_0,"Phase 2 trial received a clinical hold notice from the FDA regarding its IND application, noted December 16, 2024.","phase,regulatory",NEG,clinical hold
2816,2816_0,"Phase 1 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD, noted December 16, 2024.",phase,POS,achieved
2818,2818_0,"Phase 3 long-term topline data from OLE demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year, the treatment generally well-tolerated with low rates of adver","safety,phase,clinical",POS,well-tolerated
2819,2819_0,"Approved December 17, 2024.",catalyst,POS,Approved
2820,2820_0,"Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.","endpoint,phase,clinical",POS,met
2821,2821_0,"Phase 2b topline data reported that the trial met its primary endpoints, noted December 17, 2024.","endpoint,phase,clinical",POS,met
2822,2822_0,"Phase 1 data presented at SABCS reported that the best response rates (response only) were, CTC: 88% (7/8), noted December 17, 2024.","phase,clinical",POS,data presented at SABCS
2823,2823_0,"Phase 1/2 preliminary data from three patients in the first dose cohort of 3E13 vg/kg (Cohort 1) showed that TN-201 was generally well tolerated, with readily detectable vector DNA in the heart, evide","safety,phase",POS,well tolerated
2824,2824_0,"NDA accepted December 17, 2024.",regulatory,POS,NDA accepted
2825,2825_0,"Phase 2 study met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population, noted December","endpoint,phase",POS,met
2827,2827_0,"Phase 1 met primary endpoint of 1 year survival rate and median overall survival, noted December 17, 2024.","endpoint,phase",POS,met
2828,2828_0,"Fast track designation granted by the FDA, noted December 17, 2024.",regulatory,POS,Fast track
2829,2829_0,"Phase 3 long term extension data demonstrated that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements and relacorilant was well-tolerated, w","safety,phase",POS,well-tolerated
2831,2831_0,"Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans, noted December 17, 20",safety,POS,favorable safety
2837,2837_0,"Phase 2a data reported that DA-1241 (100mg) demonstrated a statistically significant reduction in alanine transaminase (ALT) levels at weeks 4 and 8, with a near statistically significant reduction at",phase,POS,statistically significant
2838,2838_0,"Phase 2 trial met its primary endpoint, noted December 18, 2024.","endpoint,phase",POS,met
2843,2843_0,"Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.","safety,phase",NEG,DLTs
2844,2844_0,"Phase 1/2 data reported no dose-limiting toxicities (DLTs) have been observed in the triplet combination, noted December 18, 2024.","safety,phase",NEG,DLTs
2845,2845_0,"Rolling BLA submission initiated December 18, 2024.",regulatory,POS,BLA submission
2846,2846_0,"Approved December 19, 2024.",catalyst,POS,Approved
2847,2847_0,"Phase 2b trial failed to meet its primary endpoint, noted December 19, 2024.","endpoint,phase",NEG,failed to meet
2848,2848_0,"Approved December 19, 2024.",catalyst,POS,Approved
2849,2849_0,"Approved December 19, 2024.",catalyst,POS,Approved
2850,2850_0,"Phase 2 trial met its primary endpoint, noted December 19, 2024.","endpoint,phase",POS,met
2852,2852_0,"Phase 1/2 DSMB review noted no serious adverse events, noted December 19, 2024.","safety,phase",NEG,serious adverse events
2854,2854_0,"Phase 3 met primary efficacy endpoint at Week 48, the study demonstrated to be non-inferior to BIC/FTC/TAF in double-blind trial.",phase,POS,met
2854,2854_1,The superiority criteria were not met in trial MK-8591A-052.,catalyst,POS,met
2860,2860_0,"Phase 2 trial results demonstrated that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile, noted December 19, 2024.","safety,phase",POS,favorable safety
2863,2863_0,"Phase 1 showed that 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR), noted December 19, 2024.","endpoint,phase",POS,achieved
2864,2864_0,"NDA submitted to the FDA, noted December 19, 2024.",regulatory,POS,NDA submitted
2867,2867_0,"Trial met primary endpoint, noted December 19, 2024.",endpoint,POS,met
2868,2868_0,"Approved December 19, 2024.",catalyst,POS,Approved
2871,2871_0,"Phase 3 trial met its primary endpoint, noted December 20, 2024.","endpoint,phase",POS,met
2872,2872_0,"Phase 3 trial met primary endpoint, noted December 20, 2024.","endpoint,phase",POS,met
2873,2873_0,"Approval announced December 20, 2024.",regulatory,POS,Approval
2874,2874_0,"Phase 2b/3 topline data reported a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo, noted December 20, 2024.","phase,clinical",POS,statistically significant
2875,2875_0,"Approved December 20, 2024.",catalyst,POS,Approved
2876,2876_0,"Approved December 20, 2024.",catalyst,POS,Approved
2877,2877_0,"FDA approved on December 20, 2024.",regulatory,POS,FDA approved
2878,2878_0,"CRL issued by FDA on December 20, 2024.",regulatory,NEG,CRL
2879,2879_0,"FDA Approved on December 20, 2024.",regulatory,POS,FDA Approved
2880,2880_0,"FDA Approved on December 20, 2024.",regulatory,POS,FDA Approved
2881,2881_0,"Phase 3 trial met its primary endpoint, noted December 23, 2024.","endpoint,phase",POS,met
2882,2882_0,"Phase 3 trial met its primary endpoint, noted December 23, 2024.","endpoint,phase",POS,met
2885,2885_0,"Phase 1a topline results demonstrated a favorable safety and tolerability profile with no drug-related adverse events historically associated with earlier generation, less selective BET inhibitors, no","safety,clinical",POS,favorable safety
2887,2887_0,"NDA filing submitted to the FDA, noted December 23, 2024.",regulatory,POS,NDA filing
2888,2888_0,"Phase 2 trial did not meet its primary endpoint, noted December 23, 2024.","endpoint,phase",NEG,did not meet
2890,2890_0,"FDA Approved on December 27, 2024.",regulatory,POS,FDA Approved
2891,2891_0,Phase 3 trial did not meet the primary 72-hour endpoint due to unresolved data from the final 24-hour period.,phase,NEG,did not meet
2891,2891_1,"However, the drug showed statistically significant pain reduction in the first 48 hours, n",catalyst,POS,statistically significant
2894,2894_0,"NDA filing submitted December 30, 2024.",regulatory,POS,NDA filing
2895,2895_0,"Phase 3 trial met primary endpoint, noted December 30, 2024.","endpoint,phase",POS,met
2897,2897_0,"NDA submitted to FDA, noted December 30, 2024.",regulatory,POS,NDA submitted
2899,2899_0,"Phase 3 KOASTAL-1 data reported that the trial did not meet its primary endpoint with statistical significance, noted January 2, 2025.","endpoint,phase",NEG,did not meet
2900,2900_0,"FDA ANDA approved on January 2, 2025.",catalyst,POS,approved
2901,2901_0,"FDA feedback reported that data on OS would generally not be appropriate for accelerated approval, noted January 2, 2025.","endpoint,regulatory",POS,approval
2902,2902_0,"Phase 2a data reported no SAEs and no drug-related discontinuations by study participants, noted January 2, 2025.","safety,phase",POS,no SAEs
2904,2904_0,"BLA submission to the FDA completed, noted January 2, 2024.",regulatory,POS,BLA submission
2906,2906_0,"Phase 2 trial met primary safety endpoint, noted January 6, 2025.","safety,phase",POS,met
2908,2908_0,"Phase 2b enrollment completed, noted January 6, 2024.","phase,enrollment",POS,enrollment completed
